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Monica Louise Kasting 
 
Human Papillomavirus Vaccination Status Association with Subsequent Health 
Behaviors  
Introduction 
 Human papillomavirus (HPV) infection results in serious health issues including 
cervical, anal, vulvar, penile and oropharyngeal cancers. There are three vaccines against 
HPV but vaccination rates in the United States remain low. One barrier to uptake is a 
concern that individuals who are vaccinated may increase their risky sexual behaviors or 
decrease their use of cervical cancer screenings, an adjustment in perceived level of risk 
for HPV that can be studied using risk compensation theory. 
Methods 
 Three distinct studies examined risk compensation after HPV vaccination. A 
systematic review examined literature from January 1, 2008-June 30, 2015, using three 
databases. A qualitative study using semi-structured interviews of 22 healthcare providers 
that assessed their beliefs regarding sexual disinhibition and cervical cancer screening 
following vaccination. A cross-sectional survey that assessed cervical cancer screening 
practices, awareness and comfort with recommendations, and knowledge regarding the 
purpose of a Papanicolaou (Pap) test. 
Results 
 Twenty articles were included in the systematic review. None of the studies of 
sexual behaviors and/or biological outcomes found evidence of riskier behaviors after 
HPV vaccination. Instead, the studies found vaccinated individuals were less likely to 
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report risky sexual behaviors, sexually transmitted infections (STIs), and pregnancy. 
Qualitative interviews found no healthcare providers believed the HPV vaccine would 
result in increased risky sexual behavior or decreased cervical cancer screening, and these 
concerns would not influence their vaccination recommendations. The survey included 
291 women 21-35 years old; 62% were non-Hispanic black, 84% had a Pap test in the 
last three years, and 33% had at least one HPV vaccine. Logistic regression showed that 
vaccinated women did not have greater odds of having a Pap test in the past three years 
(OR=1.32; 95% CI=0.66-2.65; p=0.427). However, this odds ratio was significant when 
controlling for age and race (AOR=3.06; 95% CI=1.37-6.83; p=0.006). 
Conclusion 
 These studies found no evidence of increased risky sexual behaviors or decreased 
cervical cancer screening rates after HPV vaccination. Furthermore, vaccinated women 
showed less evidence of risk compensation. These results should alleviate concerns about 
administering the HPV vaccination among parents and providers.  
 
Terrell Zollinger, Dr.P.H., Co-chair 
Brian E. Dixon, M.P.A., Ph.D., Co-chair 
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CHAPTER 1 
INTRODUCTION 
 
The Centers for Disease Control and Prevention (CDC) estimates 79 million 
Americans were infected with human papillomavirus (HPV) in 2015, making it the most 
common sexually transmitted infection (STI) in the U.S.1 While HPV prevalence is 
decreasing among youth, there has been no decrease in prevalence in the older 
population.2 Infection with HPV results serious health issues including cervical cancer, 
anal cancer, penile cancer, oropharyngeal cancers, genital warts, and recurrent respiratory 
papillomatosis.3 The worldwide prevalence of HPV DNA in cervical cancer is 99.7%, 
resulting in HPV being listed as having a causal role in the etiology of cervical cancer.4,5 
The CDC estimates 360,000 people get genital warts every year in the United States, 
12,000 women get cervical cancer, and over 4,000 women die from cervical cancer.1,6 
Currently there are three different HPV vaccines licensed by the U.S. Food and 
Drug Administration (FDA): a bivalent (2vHPV), a quadrivalent (4vHPV), and a nine-
valent (9vHPV) vaccine. A series of three doses is required for each vaccine.7 Detailed 
information about all of the vaccines can be found in Petrosky et al.8  The Advisory 
Committee on Immunization Practices (ACIP) recommends routine HPV vaccination for 
boys and girls age 11 or 12 and catch up vaccination for women up to age 26, all men up 
to age 21, and for men who have sex with men, up to age 26.7 The 9vHPV vaccine was 
licensed for women ages 9 to 26 and men ages 9-15 in December, 2014.9 In February, 
2015, the ACIP issued the same age-based recommendations for 9vHPV as it did for 
4vHPV.8  
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HPV vaccination rates in the U.S. remain lower than desired to best protect the 
population against HPV infection.10 In 2014, only 60.0% of adolescent girls and 41.7% of 
adolescent boys between the ages of 13 and 17 received one or more doses in the HPV 
vaccine series.11 The percentages are even lower for series completion (39.7% of girls 
and 21.6% of boys).11 Barriers to HPV vaccination include cost of the vaccine, lack of 
knowledge about HPV transmission, and parental concerns about vaccinating their 
children against a sexually transmitted infection (STI).12 Recent research has shown that 
a sizeable portion of physicians do not strongly endorse the HPV vaccine (27%) and do 
not deliver timely recommendations (26% for girls, 39% for boys).13 This is of particular 
concern because one of the strongest predictors of vaccine uptake is healthcare provider 
(HCP) recommendation and a lack of HCP recommendation has been listed as a reason 
for non-vaccination among those who are unvaccinated.14-18 An additional concern is that 
women who have received the HPV vaccine may be less likely to obtain screening for 
cervical cancer, or will cease cervical cancer screening altogether due to a perceived lack 
of susceptibility to cervical cancer.19-22 One concern among parents, clinicians, and public 
health officials, which has received particular attention in the media, is that the 
introduction of the HPV vaccine will lead to risk compensation, a concept introduced by 
Wilde in the 1980s that he called Risk Homeostasis Theory and has been used more 
broadly as Risk Compensation Theory (RCT).23 RCT suggests that individuals have 
innate set points for risk tolerance and that they change their behaviors based on 
perceived risk in order to maintain their set point. According to RCT, then, if an 
individual believes that a measure protects him/her from a certain risk, then he/she would 
be more likely to engage in risky behaviors.23 This dissertation will explore Risk 
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Compensation Theory in the context of HPV vaccination in three distinct but interrelated 
manuscripts. 
 
1.1 Theoretical Background: Risk Compensation Theory 
The idea of risk compensation has been studied for decades and G.J. Wilde 
introduced this concept in the context of seat belt use and automobile safety in the 
1980s.24 He proposed a Risk Compensation Theory that elaborated on the more well-
known Health Belief Model in order to explain risk compensation (also known as 
disinhibition). Risk Compensation Theory suggests that each individual has an innate set 
point for risk tolerance and they change their behavior based on their perceived risk. If an 
individual believes that a protective measure protects them from a certain risk, they are 
more likely to practice risky behaviors in order to get back to their set point.24 Wilde 
explains this theory in the context of seatbelt laws. His theory states there are four factors 
that influence risk: (1) The expected benefits of risky behavior alternatives (i.e. gaining 
time by speeding) (2) The expected costs of risky behavior alternatives (i.e. speeding 
tickets) (3) The expected benefits of safe behavior alternatives (i.e. insurance discounts 
for accident-free periods) and (4) The expected costs of safe behavior alternatives (i.e. 
being late). The amount of risk a person is willing to take is greater if factors 1 and 4 are 
higher and factors 2 and 3 are lower.23 
 
1.2 Risk Compensation for HPV Vaccination 
Risk compensation has been a primary concern surrounding HPV vaccination. 
There are two separate areas of concern when it comes to disinhibition and risk 
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compensation with the HPV vaccine. First, there is concern that a vaccine against an STI 
will result in adolescents engaging in more risky sexual behaviors. One study using 
qualitative interviews of mothers described it as giving girls a “carte blanche” to engage 
in behaviors that put them at risk for pregnancy, HIV, and STIs.25 Other studies have also 
found that parents had strong concerns that getting their child vaccinated for HPV would 
be seen as condoning sexual activity.12,26,27  
Parental concerns might be influenced by stories they heard in the media.28,29 A 
U.S. study found a majority of news articles about HPV vaccination were neutrally toned, 
but the results also indicated that there were several important informational facts that 
were omitted in the articles, namely information about side effects, duration of 
protection, and information about catch-up vaccination.30 Internet use and accuracy of 
internet information regarding the HPV vaccine are important considerations because 
some studies have found that vaccine concerns can be influenced by negative (and often 
inaccurate) media reports.31 Media reports and inaccurate information could cause 
parents concern prior to getting their children vaccinated, specifically in regard to risk 
compensation.  
Between 16 and 26% of parents have indicated they are concerned that HPV 
vaccination will increase the likelihood that their child will engage in riskier sexual 
behavior.32-35 However, this worry about sexual disinhibition was not usually listed as a 
reason for non-vaccination with just 3 to 6% citing it as a reason for refusing 
vaccination.36,37 The parents who did list it as a reason for non-vaccination were more 
likely to be older and have conservative political views.34,37 One qualitative study found 
that some mothers indicated they would keep the fact that HPV is sexually transmitted a 
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secret in order to reduce their worry about sexual disinhibition.31 These concerns can be 
alleviated by research examining risky sexual behavior intent following vaccination. 
Existing studies show no evidence of disinhibition due to vaccination and this effect was 
mediated by increased knowledge about HPV and the vaccine.38-41 
Secondly, an additional area that is addressed when risk compensation is 
examined is a possibility that women who have received the HPV vaccine may choose to 
get screened for cervical cancer less due to a perceived lack of susceptibility to cervical 
cancer.19,42,43 Knowledge regarding cervical cancer screening following vaccination was 
generally low among participants in one study but increased knowledge was positively 
associated with intent to get screened.39  
While there has been extensive research regarding sexual behavior intent post-
vaccination, there has been little research regarding cervical cancer screening intent and 
even less research examining actual screening behaviors post-vaccination. This 
dissertation is divided into three distinct articles all examining the concept of risk 
compensation following HPV vaccination. The conceptual model for this dissertation as 
guided by Risk Compensation Theory is shown in Figure 1.1. The aims of the dissertation 
are: 
Aim 1: To examine if there is consistent-replicated evidence in the literature of increased 
risky sexual behaviors among youth as a result of receiving the HPV vaccination. 
Aim 2: To assess health care providers’ concerns regarding risk compensation and 
whether these concerns influence their vaccination practices. 
Aim 3: To evaluate if HPV vaccination status impacts women’s cervical cancer screening 
behaviors.   
   
 6 
Figure 1.1 Dissertation Conceptual Model Using Risk Compensation Theory 
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CHAPTER 2 
TEMPEST IN A TEAPOT: A SYSTEMATIC REVIEW OF HPV VACCINATION 
AND RISK COMPENSATION RESEARCH 
2.1 Abstract 
Background 
There has been some concern among parents and in the media that vaccinating 
children against human papillomavirus could be seen as giving children permission to 
engage in risky sexual behaviors (also known as sexual disinhibition). Several studies 
have found this concern to be unfounded but there have been no attempts to synthesize 
the relevant studies in order to assess if there is evidence of sexual disinhibition. The aim 
of this study was to synthesize recent literature examining sexual behaviors and 
biological outcomes (e.g., sexually transmitted infections) post-HPV vaccination.  
Methods 
We reviewed literature from January 1, 2008, to June 30, 2015, using PubMed, 
CINAHL, and Embase with the following search terms: [(sex behavior OR sex behaviour 
OR sexual) AND (human papillomavirus OR HPV) AND (vaccines OR vaccine OR 
vaccination)] followed by a cited reference search. We included studies that examined 
biological outcomes and reported behaviors post-vaccination in both males and females. 
Studies were reviewed by title and abstract and relevant studies were examined as full-
text articles.  
Results 
We identified 2,503 articles of which 20 were eventually included in the 
systematic review. None of the studies of sexual behaviors and/or biological outcomes 
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found evidence of riskier behaviors or higher rates of STIs after HPV vaccination. 
Instead, the studies found that vaccinated compared to unvaccinated individuals were less 
likely to report vaginal intercourse without a condom (OR=0.5; 95% CI=0.4-0.6) and 
non-use of contraception (OR=0.27; 95% CI=0.15-0.48) and unvaccinated participants 
had higher rates of Chlamydia (OR=2.3; 95% CI=1.06-5.00).  
Conclusion 
These results should be reassuring to parents and health care providers. 
 
Keywords for indexing: 
Behavior, Risk compensation, Sexual disinhibition, Adolescent, HPV vaccination, 
Infectious disease, Pediatrics 
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2.2 Introduction 
In 2015, the Centers for Disease Control and Prevention (CDC) reported that 
there are approximately 79 million Americans who are currently infected with human 
papillomavirus (HPV) and 14 million new infections occur every year, making it the most 
common sexually transmitted infection (STI).1 It is estimated that the worldwide 
prevalence of HPV infection in women without cervical abnormalities is 11 to 12%. This 
varies by region with higher rates in sub-Saharan Africa (24%), Eastern Europe (21%) 
and Latin America (16%).44 Infection with HPV is a risk factor for serious health issues 
including genital warts, cervical cancer, anal cancer, penile cancer, oropharyngeal 
cancers, and recurrent respiratory papillomatosis.1 Currently, there are three different 
HPV vaccines: 1) A bivalent vaccine (2vHPV) that protects against HPV types 16 and 
18, two types that are responsible for about 70% of cervical cancer diagnoses;45 2) A 
quadrivalent vaccine (4vHPV) that protects against HPV-16 and 18 as well as HPV-6 and 
11, the two types that cause about 90% of the cases of genital warts;46 and 3)  A  nine-
valent HPV vaccine (9vHPV) was recently licensed by the U.S. Food and Drug 
Administration, and protects against the four HPV types in 4vHPV as well as five 
additional oncogenic types (HPV types 31, 33, 45, 52, and 58). The 9vHPV has the 
potential to prevent 80 to 90% of cervical cancers, and many vulvar, vaginal, and anal 
cancers in addition to 90% of genital warts.47  
Despite the recommendations made by national immunization advisory 
committees around the world, HPV vaccination rates, especially in the United States, 
remain suboptimal.10,48 For example, only 60.0% of adolescent girls and 41.7% of 
adolescent boys between the ages of 13 and 17 received one or more doses in the HPV 
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vaccine series in the United States in 2014.11 These rates are even lower when examining 
the percentages of adolescents who have completed the series, which is necessary in 
order to receive the maximum protection from the vaccine.49 Several barriers to HPV 
vaccination exist including cost of the vaccination, lack of knowledge about HPV 
transmission, and parental concerns about vaccinating their children against an STI.12 
One concern among parents, clinicians, and public health officials, which has 
received particular attention in the media, is that the introduction of the HPV vaccine will 
lead to risk compensation, a concept introduced by Wilde in the 1980s called Risk 
Compensation Theory (RCT).23 RCT suggests that individuals have innate set points for 
risk tolerance and that they change their behaviors based on perceived risk in order to 
maintain their set point. According to RCT, then, if an individual believes that a measure 
protects him/her from a certain risk, then he/she would be more likely to engage in risky 
behaviors.23 Critics of the HPV vaccine have expressed concern that the receipt of the 
vaccine could cause adolescents to engage in riskier sexual behavior due to perceived 
protection from sexually transmitted infections.21 This is a concern that has arisen 
throughout the world. For example, several Roman Catholic bishops in Canada 
discouraged vaccination, stating that school-based vaccination “sends a message that 
early sexual intercourse is allowed”50 and that abstinence is the “only truly healthy 
choice.”51,52 One study using qualitative interviews of mothers in the United Kingdom 
found it described as giving girls a “carte blanche” to engage in behaviors that put them 
at risk for pregnancy, HIV, and STIs.25  
These parental concerns might have been influenced by stories they encountered 
in the media.28,29,53 A U.S. study found a majority of news articles about HPV vaccination 
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were neutrally toned but the results also indicated that there were several important 
informational facts that were omitted in the articles, namely information about side 
effects, duration of protection, and information about catch-up vaccination.30 Internet use 
and accuracy of internet information regarding the HPV vaccine are important 
considerations because some studies have found that vaccine concerns can be influenced 
by negative (and often inaccurate) media reports.31 Media reports and inaccurate 
information could cause parents concern prior to getting their children vaccinated, 
specifically in regard to risk compensation.  
Across several studies between 16% and 26% of parents indicate that they were 
concerned that HPV vaccination would increase the likelihood that their child would 
engage in riskier sexual behavior.32-35 However, this worry about sexual disinhibition was 
not usually listed as a reason for non-vaccination, and only 3 to 6% of parents cited this 
concern as a reason for refusing vaccination.36,37  
The objective of the present study was to conduct a systematic review of research 
literature to evaluate whether there is evidence (via either self-report of sexual behaviors 
or biological outcomes such as sexually transmitted infections) of sexual disinhibition 
following HPV vaccination.  Our aims were to answer the following research questions: 
1) Is there consistent, replicated evidence of increased self-reported risky sexual 
behaviors after HPV vaccination? and 2) Is there consistent, replicated evidence of 
increased incidence of sexually transmitted infections or pregnancies after HPV 
vaccination? 
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2.3 Materials and Methods 
 A systematic review of the literature was performed using the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol and searching the 
PubMed, CINAHL, and Embase databases. The following search terms were used: [(sex 
behavior OR sex behaviour OR sexual) AND (human papillomavirus OR HPV) AND 
(vaccines OR vaccine OR vaccination)] and the results were limited to studies from 
January 1, 2008, to June 30, 2015. The January 1, 2008, start date was chosen in order to 
capture articles examining behaviors post-vaccination. The 4vHPV was first licensed in 
the U.S. in mid-2006 and the Advisory Committee on Immunization Practices (ACIP) 
voted to routinely recommend it for girls in June 2006, at which point it was covered by 
the majority of insurers.54 These recommendations were published in the Morbidity and 
Mortality Weekly Report in March 2007.55 Therefore, relevant research examining post-
vaccination behaviors was not published until 2010. Nevertheless, the 2008 start date for 
the search was chosen as a conservative estimate in order to ensure that we captured all 
relevant research.  
To answer the outlined research questions, study outcomes were divided into two 
groups: self-reported behaviors (age at sexual initiation, reported number of sexual 
partners, and reported condom usage), and biological outcomes (pregnancy and STI 
diagnoses). Articles were included if they examined reported behaviors and/or biological 
outcomes post-vaccination. Studies were not restricted by age, gender, or geographic 
location. Articles were excluded if they examined worry or behavioral intent but not 
actual behaviors. Studies were also excluded if they were not original, peer-reviewed 
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research articles (e.g. published abstracts for conferences, press releases, or commentaries 
on other articles).   
First, studies were screened for inclusion by reviewing the titles and abstracts 
(MLK & GKS). Additional studies were excluded by a closer examination of the 
remaining abstracts (MLK & GDZ). The remaining studies were examined as full-text 
articles. Two authors independently reviewed each study to determine the relevance for 
inclusion. Each reviewer completed a data extraction and quality assessment sheet for 
each article. Most of the quality assessment tools for systematic reviews were developed 
and validated for intervention research.56-59 The data extraction sheet used in this 
systematic review was developed by combining relevant portions of previously validated 
data quality assessment tools from the Agency for Healthcare Research and Quality's 
(AHRQ), Cochrane, PRISMA, and the NIH Quality Assessment Tool for Observational 
Cohort and Cross-Sectional Studies.  
 
2.4 Results 
2.4.1 Study Characteristics 
The initial search of the three databases resulted in 2,503 returns. Once duplicates 
were deleted, 1,584 articles remained. After screening by title and abstract, there were 29 
full-text articles to be reviewed by all of the authors. The final selection resulted in 20 
articles being included in this study. For the full PRISMA flow diagram, see Figure 2.1.  
Of the 20 studies included in this systematic review, 2 were qualitative, 12 were 
cross-sectional, and 8 were longitudinal studies. It is important to note that these 
categories are not mutually exclusive. If a study used more than one study design and the 
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results were presented separately, it was counted in both relevant categories. Although we 
searched for studies between 2008 and 2015, the relevant studies for this review were 
published between 2011 and 2015. Furthermore, although we did not restrict by age or 
gender, all of the studies examined exclusively female populations and all of them 
studied populations within the 10 to 46 year-old age range. The descriptive statistics of 
the included studies are reported in Table 2.1. The full list of qualitative, cross-sectional, 
and longitudinal study results from the review are included as Tables 2.2, 2.3, and 2.4, 
respectively.  
Figure 2.1 PRISMA Flow Diagram 
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Table 2.1 Descriptive Statistics and Quality Assessment 
Total Studies (20) N (%) 
Study Design  
      Qualitative 2 (10%) 
      Cross-Sectional 12 (60%) 
      Cohort 8 (40%) 
Used Unvaccinated Control Group 16 (80%) 
Outcome Assessed  
      Behavioral 17 (85%) 
        Reported Sexual Activity 12 (60%) 
         Age at Sexual Debut 7 (35%) 
         Number of Partners 13 (65%) 
         Contraception Use 16 (80%) 
      Biological 9 (45%) 
         STI Testing/Diagnosis 6 (30%) 
         Pregnancy/Abortion/Composite Measure 5 (25%) 
Average Study Quality Score (1-10) 6.2 
 
   
 
1
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Table 2.2 Qualitative Studies 
First author, year, 
location 
Data collection 
method, date 
Participant details Analysis Primary Findings 
*Aujo, 2014, 
Uganda60 
Semi-structured focus 
groups, date unclear 
52 girls aged 12-15 
years old 
Thematic 
analysis 
Vaccinated and unvaccinated girls 
engaged in sexual activity. Effect 
vaccination might have on sexual 
behaviors had varying responses.  
Ports, 2014, United 
States61 
Semi-structured 
individual phone 
interviews, 2013 
30 women 19-25 
years old (mean 
age=28.87), 
received all 3 HPV 
vaccine doses 
Thematic 
analysis 
83% said that having been vaccinated 
against HPV had no influence on their 
romantic relationships and did not have 
any effect on their participation in safer 
sex (50%). 27% reported that getting 
vaccinated made them more aware of 
sexually transmitted diseases, and more 
cautious with sexual activity. 
* Aujo et al. (2014) utilized both qualitative and cross-sectional study designs and as such is listed in both tables. Only the results 
from the qualitative portion of the study are reported in this table.  
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Table 2.3 Cross-Sectional Studies 
First author, 
year, location 
Data collection 
method, date  
Participant Details Outcomes 
assessed 
Main findings 
  Study 
population 
Comparison 
population 
  
*Aujo, 2014, 
Uganda60 
Survey 
questionnaire, 
vaccination status 
verified through 
vaccine registry, 
date unclear 
200 girls 12-
15 years old 
(m=12.8) 
from 
Nakasongola 
district, HPV 
vaccinated 
200 girls 12-
15 years old 
(m=13.1) 
from Luwero 
district, HPV 
unvaccinated 
Behavioral 
outcomes: Sexual 
intercourse any 
time from the time 
of HPV 
vaccination or any 
time from 10 years 
of age for 
unvaccinated 
No significant differences were 
found between groups for sexual 
activity. 
**Forster, 
2012, United 
Kingdom62 
Survey 
questionnaire, 2009 
 
433 girls 16-
17 years old 
(m=17.1) 
from four 
schools that 
offered 
school-based 
HPV 
vaccination 
620 girls 16-
17 years old  
(m=17.0) 
from three 
schools that 
did not offer 
school-based 
HPV 
vaccination 
Behavioral 
outcomes: 
reported number 
of sexual partners, 
age at sexual 
debut 
The group that had been offered the 
vaccine was not significantly more 
sexually active than the group that 
had not been offered the vaccine 
(41.2% vs 41.6%; OR=.98; 95% 
CI=0.7-1.4). 
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Table 2.3 Cross-Sectional Studies (continued) 
Hansen, 2014, 
Denmark, 
Norway, 
Sweden63 
Self-administered 
structured 
questionnaire, 
2011-2012.  
 
Sociodemographic 
data were obtained 
from Statistics 
Denmark, Statistics 
Norway and 
Statistics Sweden  
3,805 women 
18-46 years 
old, received 
HPV vaccine 
40,247 
women 18-
46 years old, 
had not 
received 
HPV vaccine  
 
Behavioral 
outcomes: age at 
first intercourse, 
non-use of 
contraception 
during first 
intercourse, the 
number of sexual 
partners 
The rates of sexual debut and 
number of sexual partners did not 
differ significantly for women who 
were vaccinated before sexual debut 
and unvaccinated women. 
Vaccinated participants were less 
likely to have had 4+ partners before 
age 18 (AOR=0.56; 95% CI=0.40-
0.78), and report non-use of 
contraception during first intercourse 
(AOR=0.27; 95% CI=0.15-0.48). 
Liddon, 2012, 
United States64 
National Survey of 
Family Growth, 
2007-2008.   
 
 
279 females 
15-24 years 
old, received 
HPV vaccine  
964 females 
15-24 years 
old, had not 
received 
HPV vaccine 
Behavioral 
outcomes: age at 
first sex (older or 
younger than 15), 
lifetime number of 
partners, 
consistent condom 
use in the past 4 
weeks 
Biological 
outcomes: 
received STD 
service in the last 
year 
 
 
No significant differences were 
found between groups for lifetime 
sex partners, consistent condom use 
in the past 4 weeks, and having 
received an STD service in the past 
year. 
Compared with those who reported 
never using a condom, participants 
always using a condom were more 
likely to report receipt of HPV 
vaccine (AOR=3.0, 95% CI=1.1-
7.9). 
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Table 2.3 Cross-Sectional Studies (continued) 
Lutringer-
Magnin, 2013, 
France42 
Self-administered 
questionnaire, 
2008- 2009 
135 females 
14-23 years 
old, received 
HPV vaccine 
181 females 
14-23 years 
old, had not 
received 
HPV vaccine 
Behavioral 
outcomes:  
Condom use 
(during first and 
most recent sexual 
intercourse), 
condom use 
behavior (non-
risky, 
indeterminate, 
etc.), time in years 
from first sexual 
intercourse, 
number of 
partners, history of 
emergency, 
contraception,  
Biological 
outcomes: 
abortion, requests 
for HIV serology 
No significant differences were 
found between groups for sexual 
activity, requests for HIV serology, 
history of abortions, or emergency 
hormonal contraception. 
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Table 2.3 Cross-Sectional Studies (continued) 
Marchand, 
2013, United 
States65 
Web-based survey, 
9/2011-11/2011 
42 female 
students 18-
26 years old, 
received any 
doses of HPV 
vaccine 
72 female 
students 18-
26 years old, 
had not 
received 
HPV vaccine 
Behavioral 
outcomes: ever 
had sex with 
anyone of the 
opposite sex, age 
at first intercourse, 
number or partners 
in the last year, 
frequency of 
condom use in the 
last year  
 
No significant differences were 
found between groups for any sexual 
behaviors including age at first 
intercourse (p=0.32), number of 
partners (p=0.97), or frequency of 
condom use (p=0.94) in either the 
bivariate or the multivariate 
analyses. 
Mather, 2012, 
Australia43 
Web-based survey, 
5/2011-8/2011 
119 women 
18-29 years 
old (m=19.2), 
received any 
doses of HPV 
vaccine 
74 women 
18-30 years 
old 
(m=19.5), 
had not 
received 
HPV vaccine 
Behavioral 
outcomes: condom 
use, monogamous 
for more than 3 
months  
Vaccinated participants were more 
likely to be sexually active (61.3%) 
than non-vaccinated participants 
(45.9%) [p<.05]. Among subsample 
of sexually active participants, no 
significant differences were found 
between groups for safer sexual 
behavior (p=0.84) or consistent 
condom use (p=0.88), after 
controlling for effects of age. 
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Table 2.3 Cross-Sectional Studies (continued) 
Mattebo, 2014, 
Sweden66 
Written self-report 
questionnaire 
completed in 
classroom (n=338) 
or via mail (n=17), 
1/2013-3/2013 
227 girls 17-
21 years old 
(median=18), 
received any 
doses of HPV 
vaccine 
121 girls 17-
21 years old 
(median=18)
, had not 
received 
HPV vaccine 
Behavioral 
outcomes: 
experience of 
intercourse, 
condom use 
during intercourse, 
oral sex, 
protection during 
oral sex, anal sex, 
protection during 
anal sex, group 
sex, friends-with-
benefits 
relationship, one 
night stand.  
Biological 
outcomes: Self-
reported history of 
STI diagnosis 
No significant differences were 
found between groups for STIs, 
condom use (p=0.79), oral sex 
(p=0.15), anal sex (p=0.80), group 
sex (p=0.80). 
Vaccinated participants were more 
likely to have initiated intercourse 
(84%) than non-vaccinated 
participants (70%; p<.005). 
Vaccinated participants more likely 
to report a one-night stand (41%) 
than non-vaccinated (29%; p<.04). 
 
 
Ratanasiripong, 
2014, United 
States67 
Web-based survey, 
Spring 2012 
209 females 
18-26 years 
old (m=20.75 
in total 
sample), 
received any 
doses of HPV 
vaccine 
175 females 
18-26 years 
old, had not 
received 
HPV vaccine  
Behavioral 
outcomes: number 
of lifetime sex 
partners, number 
of sex partners in 
the last year, age 
at initiation, 
condom use. 
No significant differences were 
found between groups for condom 
use (p=.98), lifetime sexual partners 
(p=.39), number of sexual partners in 
the last year (p=.98), number of 
partners before and after vaccination 
(p=.07).  
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Table 2.3 Cross-Sectional Studies (continued) 
Ruiz-Sternberg, 
2014, 
Colombia68 
Self-administered 
survey, 5/2011-
3/2012 
506 women  
up to 26 years 
old (m=19.6) 
930 women 
up to 26 
years old 
(m=19.5) 
Behavioral 
outcomes: ever 
had sex, initiation 
before 15 years 
old, more than 3 
sex partners, 
condom use, 
contraception use 
No significant differences were 
found between groups for initiation 
of sexual intercourse before 15 years 
of age (p=0.167), number of sexual 
partners (p=0.381), and use of 
alcohol or drugs at last intercourse 
(p=0.553).  
Vaccinated adult women were more 
likely to have had sex (OR=1.89) but 
also showed more consistent 
condom use (OR=1.49), and 
contraception use (OR=2.02) 
Rysavy, 2014, 
United States69 
Computer assisted 
interviews, 2009-
2011 
153 girls 13-
23 years old 
(m=19.2), 
received HPV 
vaccination 
70 girls 13-
23 years old 
(m=20.1), 
had not 
received 
HPV vaccine  
Behavioral 
outcomes: Age at 
initiation, number 
of partners, 
condom use, age 
at anal and oral 
intercourse   
Biological 
outcomes: STI 
diagnosis, 
pregnancy 
No significant differences were 
found between groups for age at first 
intercourse (p=0.768), number of 
partners (p=0.513), condom use 
(p=0.407), and STI diagnoses (p-
values ranging from 0.242 to 0.763).  
Non-vaccination as associated with 
having been pregnant (20% vs 8.6%; 
p=0.016) in bivariate analysis; 
however, this difference was not 
significant in multivariate 
regression. 
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Table 2.3 Cross-Sectional Studies (continued) 
Sadler, 2015, 
United 
Kingdom70 
Data collection 
method unclear, 
9/2010-10/2011  
231 women 
14-20 years 
old (m=18 for 
total sample), 
received at 
least one dose 
of the HPV 
vaccine 
132 women 
14-20 years 
old, 
unvaccinated 
Behavioral 
outcomes: age at 
first intercourse, 
condom use, anal 
intercourse, drugs, 
alcohol, number of 
partners, 
emergency 
contraception use, 
sexual activity 
abroad 
Biological 
outcomes: history 
of abortion, 
received STI 
treatment, STI 
symptoms 
Non-vaccination positively 
associated with: having more than 
three partners in the last 6 months 
(OR=2.12; 95% CI=1.08-4.17), 
attending the clinic with symptoms 
(OR=1.78; 95% CI=1.09-2.92), 
having anal intercourse with their 
last sexual contact (OR=4.34; 95% 
CI=1.23-14.29) and receiving a 
positive C. trachomatis diagnosis 
from the clinic (OR=2.3; 95% 
CI=1.06-5).  
Vaccination positively associated 
with condom use at first intercourse 
(OR=0.55; 95% CI=0.32-0.96). 
*Aujo et al. (2014) utilized both qualitative and cross-sectional study designs and as such is listed in both tables. Only the results from 
the cross-sectional portion of the study are reported in this table.  
**Forster et al. (2012) utilized both cross-sectional and longitudinal study designs and as such is listed in both tables. Only the results 
from the cross-sectional portion of the study are reported in this table.  
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Table 2.4 Longitudinal Studies 
First 
author, 
year, 
location 
Data 
collection 
method, date  
Participant Details Outcomes assessed Length of 
Follow-Up 
Main findings 
Study 
population 
Comparison 
population 
Al Romaih, 
2011, United 
States71 
Chart audits, 
date not 
reported 
499 female 
adolescents, 
(mean age= 
16.05), all 
vaccinated 
Pre-, post- 
design, each 
girl served as  
her own 
control 
Behavioral 
outcomes: self-
reported sexual 
activity and number 
of sexual partners 
Outcome was 
assessed prior to 
vaccination (at 
an unspecified 
time interval), at 
vaccination, and 
one-year post 
vaccination. 
No significant 
differences in 
reported sexual 
activity or number of 
partners before and 
after vaccination. No 
statistical analysis 
reported. 
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Table 2.4 Longitudinal Studies (continued) 
Bednarczyk, 
2012, United 
States41 
Electronic 
medical 
record audits, 
2006-2007, 
follow-up 
through 2010 
493 females 
11-12 years 
old 
(m=11.9), 
received at 
least 1 HPV 
vaccine 
905 females 
11-12 years 
old (m= 11.6), 
received no 
HPV vaccines 
Biological outcomes: 
“Testing/Diagnosis/ 
Counseling” (any 
occurrence of testing 
for C. trachomatis or 
pregnancy; 
diagnoses of C. 
trachomatis 
infection, pregnancy, 
or VD-NOS; and 
physician counseling 
on contraceptives). 
“Diagnosis Only” 
(any occurrence of 
diagnostic outcomes 
for C. trachomatis 
infection, pregnancy, 
or VD-NOS) 
3 years 
retrospective 
No significantly 
increased incident rate 
ratios were found for 
outcomes comparing 
HPV vaccine–
exposed and 
unexposed girls. This 
includes STI 
testing/diagnosis 
(IR=1.29; 95% 
CI=0.92-1.80), and 
pregnancies (IR=1.89; 
95% CI=0.33-10.79) 
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Table 2.4 Longitudinal Studies (continued) 
Brown, 
2013, Peru72 
Sequential 
survey data; 
date not 
reported 
200 female 
sex workers, 
18-26 years 
old 
(m=22.9), all 
received at 
least 1 HPV 
vaccine 
No 
comparison 
group 
Behavioral 
outcomes: reported 
sex with new clients, 
reported condom use 
7 months 
prospective 
Reported sexual 
activity with all 
clients decreased 
significantly from day 
0 to month 7 
(p<0.001). Frequency 
of reported 
intercourses with new 
clients over the same 
time period was lower 
(p< 0.001). Reported 
condom use with all 
clients and with non-
paying partners did 
not change over time. 
Number of FSWs 
having nonpaying 
sexual partners 
increased significantly 
(OR=3.96; 95% 
CI=1.88-8.35) as did 
frequency of 
intercourse with non-
paying sexual partners 
(p<0.001).  
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Table 2.4 Longitudinal Studies (continued) 
Cummings, 
2012, United 
States73 
Study 
population- 
questionnaire, 
in-person 
interview, 
self-collected 
vaginal swab; 
2010 
Controls- 
questionnaire, 
in-person 
interview, 
clinician 
obtained or 
self-collected 
vaginal swab; 
1999-2005 
75 females 
14-17 years 
old 
(m=15.5), 
received at 
least 1 HPV 
vaccine 
150 females 
(2:1 match) 
14-17 years 
old (m=15.3), 
unvaccinated 
Behavioral 
outcomes: number of 
sex partners in the 
last 2 months, 
frequency of sexual 
activity, condom use; 
Biological outcomes: 
Gonorrhea, 
chlamydia, 
Trichomoniasis 
diagnoses, HPV-type 
prevalence. 
Comparison 
group: 2 years 
retrospective 
Study 
population: one-
time 
questionnaire 
Instances of vaginal 
intercourse without a 
condom (over the last 
2 months) were 
significantly lower in 
the vaccinated as 
compared to those in 
the unvaccinated (p< 
0.001). This was the 
only sexual behavior 
found to be different 
between the two 
cohorts. No 
significant differences 
were found in 
chlamydia and 
Trichomoniasis rates 
between the 
unvaccinated and 
vaccinated cohorts. 
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Table 2.4 Longitudinal Studies (continued) 
**Forster, 
2012, United 
Kingdom62 
Sequential 
survey data, 
2009-2010 
148 females 
16-17 years 
old 
(m=17.5), 
received at 
least one 
HPV vaccine 
259 females 
16-17 years 
old (m=17.5), 
received no 
HPV vaccines 
Behavioral 
outcomes: sexual 
debut, number of sex 
partners, condom use 
6 months 
prospective 
The change in the 
proportion of girls 
who were sexually 
active from baseline 
to follow-up was not 
significantly greater 
in the vaccinated 
group than the 
unvaccinated group 
(OR=0.80; 95% CI= 
0.04–1.59). 
The change in number 
of sexual partners 
from baseline to 
follow-up was not 
significantly different 
between groups (p= 
0.38). Change in 
condom use between 
baseline and follow-
up did not differ by 
vaccination group 
(OR=0.88; 95% CI= 
0.58–1.33). 
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Table 2.4 Longitudinal Studies (continued) 
Jena, 2015, 
United 
States40 
Medical and 
pharmaceutica
l claims, 
2005-2010 
21,610 
females 12-
18 years old 
(m= 15.0), 
vaccinated 
against HPV 
n=186,501 
age-matched 
females 12-18 
years old (m= 
14.9), not 
vaccinated 
against HPV 
Biological outcomes: 
at least one medical 
claim for any of the 
following: 
chlamydia, 
gonorrhea, herpes, 
human 
immunodeficiency 
virus or AIDS, or 
syphilis. 
One year before 
vaccination to 
one year after 
vaccination 
The rates of STIs in 
the year before 
vaccination were 
higher among HPV-
vaccinated females 
compared with age-
matched non-
vaccinated females 
(AOR=1.37; 95% CI= 
1.09-1.71). The rates 
of STIs increased for 
the vaccinated and 
nonvaccinated groups 
in the year after 
vaccination. The 
difference-in-
difference odds ratio 
was 1.05 (95% CI= 
0.80-1.38), implying 
that HPV vaccination 
was not associated 
with an increase in 
STIs. Similar 
associations held 
among age subgroups. 
   
 
3
0
 
Table 2.4 Longitudinal Studies (continued) 
Mayhew, 
2014, United 
States74 
Sequential 
survey data, 
date not 
reported 
339 females 
13-21 years 
old 
(m=16.8), 
received at 
least one 
HPV vaccine 
No 
comparison 
group 
Behavioral 
outcomes: initiation 
of sexual intercourse, 
perceived risk for 
STIs other than HPV 
after vaccination, 
perceived need for 
safer sexual 
behaviors after 
vaccination, sexual 
behaviors at 2 and 6 
month follow up 
appointments. For 
sexually 
inexperienced at 
baseline: sexual 
initiation. For 
sexually experienced 
at baseline: number 
of sexual partners, 
condom use at last 
intercourse. 
6 months 
prospective 
No significant 
associations between 
risk perceptions and 
subsequent sexual 
behaviors among all 
sexually 
inexperienced and 
experienced 
participants (p=0.59). 
In age-stratified 
analyses of sexually 
inexperienced 
participants: those 16 
to 21 years of age 
who had higher scores 
on the scale 
measuring perceived 
risk for STIs other 
than HPV, indicating 
lower perceived risk 
for other STI (an 
inappropriate 
perception) were less 
likely to initiate sex 
over the next 6 
months. (OR=0.13; 
95% CI= 0.03-0.69). 
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Table 2.4 Longitudinal Studies (continued) 
Smith, 2015, 
Canada75 
Audit of 
population-
based 
administrative 
database 
128,712 
females, 13-
17 years old 
(m=13.17 for 
total sample 
at cohort 
entry), 
eligible for 
the HPV 
vaccination 
program 
131,781 
females, 13-
15 years old 
(m=13.17 for 
total sample at 
cohort entry), 
not eligible 
for HPV 
vaccination 
program 
Biological outcomes: 
a composite measure 
of incident 
pregnancy and non–
HPV-related 
sexually transmitted 
infections. These 
were also assessed 
separately.  
 
4 years (grade 8 
to grade 12) 
Controlling for birth 
timing in the year, no 
statistically 
significant increase in 
risk of the composite 
measure (OR=0.98; 
95% CI=0.84-1.14), 
pregnancy (OR=1.00; 
95% CI=0.83-1.21), 
or STIs (OR=0.81; 
95% CI=0.63-1.04) in 
relation to HPV 
vaccination. 
**Forster et al. (2012) utilized both cross-sectional and longitudinal study designs and as such is listed in both tables. Only the results 
from the longitudinal portion of the study are reported in this table.  
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2.4.2 Critical Appraisal of the Studies 
 The 20 studies were divided among all of the co-authors, such that each study was 
reviewed by two co-authors, who then filled out corresponding data extraction sheets (the 
data extraction sheet used for this study is provided as Appendix A). The data extraction 
sheet contained items from previously validated data quality assessment tools including 
the Agency for Healthcare Research and Quality's (AHRQ), Cochrane, PRISMA, and the 
NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. 
Items on the data extraction sheet included assessment of study design, 
inclusion/exclusion criteria, study population and comparison group, length of follow-up, 
outcomes, limitations, generalizability, and an assessment of overall study quality. 
Overall study quality was assessed by each coauthor on a scale of 1-10 with higher 
numbers indicating greater study quality. The authors were given criteria with which to 
judge the studies and if the quality assessment from each author varied by more than two 
points, disagreements were resolved through discussion. The study’s quality score was 
then averaged between the two reviewers’ scores. Average study quality score ranged 
from 1.8 to 9.0 (mean=6.2; standard deviation=2.04). 
 
2.4.3 Behavioral Outcomes 
 All but three studies examined self-reported behavioral outcomes (n=17, 85%). A 
widely studied behavior was sexual activity, which was assessed in many of the studies 
included in the review (n=12) but was only statistically evaluated in 10 of the studies. 
Sexual activity was defined differently across studies, and included reported sexual 
intercourse any time after receipt of HPV vaccine (or any time after 10 years of age for 
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the unvaccinated controls),60 ever having sex with someone of the opposite sex,65 and any 
experience of intercourse.66,74 Other behaviors examined in the studies were: age at 
sexual debut (n=7), number of sexual partners (n=13), use of contraception (n=16), and 
other sexual risk behaviors (n=5).  
 
2.4.3.1 Self-Reported Sexual Activity 
 One study, by Aujo et al. (2014), used both qualitative and quantitative methods 
to examine self-reported sexual activity in two different communities (one vaccinated and 
one unvaccinated community) in Uganda. The qualitative component of the study found 
that most girls indicated they were not engaged in sexual activity themselves but they 
knew of others who were. The cross-sectional survey portion of the study found that 
young girls engaged in sexual activity in both the vaccinated and unvaccinated districts, 
but vaccinated girls had a lower reported rate of sexual intercourse than unvaccinated 
girls (1.5% vs. 2.5%).60  
The majority of the studies examining self-reported sexual activity were cross-
sectional in nature and some of these cross-sectional studies did find that vaccinated 
participants were more likely to have engaged in sexual intercourse than unvaccinated 
participants.43,66,68 However, these studies also noted that many of their participants 
(between 45% and 62%) were sexually active prior to HPV vaccination.65,66 Due to the 
cross-sectional nature of these studies, these results may be more indicative of a woman 
engaging in sexual behavior and then seeking out protective measures as opposed to the 
vaccination causing the increased sexual behavior. Furthermore, previous studies have 
shown that providers are more likely to offer or strongly recommend the vaccine to 
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patients they believe are sexually active or are not in a monogamous relationship.13,76,77 
Other cross-sectional studies found no statistical difference in sexual activity between 
vaccinated and unvaccinated participants (odds ratios between 0.88 and 1.07).42,62-64  
The longitudinal studies did not demonstrate that vaccinated women were more 
sexually active than unvaccinated women when post-vaccination behavior change was 
assessed. Some of these studies found that there was no statistically significant difference 
in baseline to follow-up sexual activity between vaccinated and unvaccinated 
women,62,71,73 while others found decreases in sexual activity after vaccination. One 
study of female sex workers conducted by Brown et al. (2013) in Peru found female sex 
workers decreased sexual activity with all clients after vaccination (p<0.001).72 And 
another study (Mayhew et al. 2014) of a fully vaccinated sample found that participants 
between 16 and 21 years of age who inappropriately perceived lower risk for non-HPV 
STIs after vaccination were actually less likely to initiate sex over the following six 
month period (OR=0.13; 95% CI= 0.03-0.69).74  
 
2.4.3.2 Self-Reported Age at Sexual Debut 
 Seven of the studies examined age at first intercourse as a risky behavior post-
vaccination. The studies defined the variable differently with some looking at age as a 
continuous variable and some categorizing the variable as sexual debut before or after a 
certain age (usually 15 or 16). Regardless of how the variable was defined, none of the 
studies that examined age at sexual debut found a statistically significant difference 
between vaccinated and unvaccinated groups.63,65,67-70 Only one study (Liddon et al. 
2012) found an association between HPV vaccine and age at first intercourse. But this 
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was only significant in the bivariate model of a subset of 20 to 24 year olds and was not 
significant in the multivariable model.64 
 
2.4.3.3 Self-Reported Number of Sexual Partners 
Most of the studies examining the number of sexual partners between groups 
found no association between vaccination status and number of partners. This result held 
true in cross-sectional studies when the researchers examined number of lifetime 
partners,42,62-65,67-69 number of partners in the last 12 months,67 and number of partners 
before 18 years of age.63 It also held true in studies that followed cohorts longitudinally, 
which found vaccinated women did not have more sexual partners at follow-up.62,71,73 A 
Mayhew et al. (2014) study of a fully vaccinated sample did not see a significant increase 
in the number of sexual partners after the sample was vaccinated.74 
In fact, some of the studies found that vaccinated women had fewer sexual 
partners than unvaccinated women. One population-based study of Nordic women 
(Hansen et al., 2014) found that women who were vaccinated opportunistically (i.e., 
those that were vaccinated but not during an organized vaccination program) were 
significantly less likely than unvaccinated participants to have had four or more partners 
before reaching age 18 (AOR=0.56; 95% CI= 0.40-0.78).63 A similar finding was 
reported in a study conducted by Sadler et al. (2015) in the United Kingdom that found 
that non-vaccination was positively associated with having three or more partners in the 
last six months (OR=2.12; 95% CI=1.08-4.17).70 A study conducted by Lutringer-
Magnin et al. (2013) in France, found that vaccinated girls between the ages of 17 and 20 
had had fewer partners than unvaccinated girls (p=0.01).42 Furthermore, a study of 
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Peruvian female sex workers by Brown et al. (2013) found that participants had a 
significantly lower frequency of intercourse with new clients after vaccination 
(p<0.001).72 
 
2.4.3.4 Use of Contraception 
 Several of the studies examined use of contraception. Some assessed condom use 
while others examined use of hormonal contraception or counseling on contraception. 
While there has been some concern that an erroneous belief that the HPV vaccine 
protects against all STIs would result in a decrease in condom use, a study examining risk 
perceptions found that this erroneous belief did not result in decreased condom use.74 A 
qualitative study by Ports et al. (2014) found that none of the women they interviewed 
reported that the HPV vaccine had an influence on their use of condoms during sexual 
activity.61 Cross-sectional studies assessing condom use utilized different definitions for 
their studies including an assessment of general condom use,66,67,69 consistent condom use 
in the last month,64 condom use during most recent intercourse,42 condom use during first 
intercourse,42,70 and consistent condom use during all sexual encounters.43,65,67,68 
Regardless of how condom use was defined, none of the aforementioned studies found 
any statistically significant relationship between HPV vaccination and condom use. 
However, some studies did note that vaccinated women were more likely to take 
protective measures and found a positive association between condom use and HPV 
vaccination. A study by Hansen et al. (2014) found that non-use of contraception during 
first intercourse was significantly less frequent among women who were vaccinated 
before sexual debut as opposed to their matched unvaccinated counterparts (OR=0.27; 
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95% CI=0.15-0.48 for those vaccinated during an organized vaccination program; 
OR=0.69; 95% CI=0.52-0.93 for those vaccinated opportunistically).63 Liddon et al. 
(2012) found that a higher percentage of those who reported always or at least 
inconsistently using condoms reported being vaccinated as opposed to those who never 
used condoms.64 Ruiz-Sternberg et al. (2014) reported a similar finding, that vaccinated 
women were more likely to report consistent condom use than unvaccinated women.68 
Additionally, Sadler et al. (2015) reported condom use at first intercourse was positively 
associated with HPV vaccination (OR=0.55; 95% CI=0.32-0.96).70 There were two 
studies that examined use of emergency hormonal contraception (Lutringer-Magnin et al. 
2013 and Sadler et al. 2015). Neither study found any differences in the use of 
emergency contraception between those who had been vaccinated and those who had 
not.42,70  
Contraceptive behavior was also examined by several longitudinal studies. 
Bednarczyk et al. (2012) used data from a managed care organization to assess the 
relationship between a patient seeking counseling on contraceptives and HPV 
vaccination. This study found that vaccinated participants were more likely to seek 
counseling on contraceptive use as opposed to unvaccinated participants, although the 
adjusted incident rate ratio was not significant (OR=2.31; 95% CI=0.99-5.38).41 This 
result is consistent with a study by Forster et al. (2012) that found no change in condom 
use from baseline to follow up by vaccination group (OR=0.88; 95% CI=0.58-1.33).62 A 
study of female sex workers found no change in condom use with all clients after 
vaccination but they did note that condom use with non-paying partners increased, 
although not significantly (p=0.38).72 Another longitudinal study (Cummings et al. 2012) 
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found instances of vaginal intercourse without a condom over the last two months was 
significantly lower in the vaccinated group (p<0.001).73 The findings from all of the 
studies combined demonstrated that there was either no association between HPV 
vaccination and condom use/contraception counseling or they demonstrated that 
vaccinated participants engaged in safer behaviors than unvaccinated participants.  
 
2.4.3.5 Other Risk Behaviors 
 Many of the included studies also examined risky behaviors that did not fit in the 
above categories. Several of the studies examined relationship status. Most of them 
defined being in a monogamous relationship as a “safe” behavior and being in non-
exclusive relationships or having “one-night stands” as constituting “unsafe” behavior. 
One study conducted in Uganda that used dating and sexual activity as measures of risky 
behavior found that unvaccinated girls were dating at higher rates than vaccinated girls 
(5% vs. 2.5%) but the authors did not assess if those specific dating relationships 
involved risky sexual behaviors.60 Another study (Mather et al. 2012) compared “safe 
sexual behavior” between vaccinated and unvaccinated individuals by creating a 
composite measure that included condom use, use of other contraception, and having 
been in a monogamous relationship for at least three months. Using this measure, authors 
found no relationship between HPV vaccination and engaging in safe sexual behavior.43 
Rysavy et al. (2014) used a similar technique to examine “high risk sexual behaviors” 
such as frequency of condom use, number of partners, as well as experience of anal and 
oral intercourse, and age at first anal and oral intercourse to create a risk behavior score. 
This study found that there were no differences between the vaccinated and unvaccinated 
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groups on the composite risk behavior score.69 This relationship was still not significant 
when the high risk behaviors were examined individually. Another study (Mattebo et al. 
2014) examined high risk behaviors individually and assessed the effect of experiencing 
“one-night stands,” group sex, “friends with benefits” relationships, oral sex, and anal 
sex. In this study the authors did find that vaccinated women were more likely to have 
experienced a one-night stand (p=0.046) but this cross-sectional study noted that 62% of 
their sample had reached sexual debut before vaccination so the temporal relationship 
between sexual experience and vaccination cannot be assessed and it is possible a person 
engaging in high-risk sexual behaviors was more likely to seek vaccination.66 
Furthermore, this study found no differences when comparing vaccinated and 
unvaccinated individuals with respect to experiencing a “friends with benefits” 
relationship, group sex, giving oral sex, receiving oral sex, or anal sex.66 Lastly, a cross-
sectional study examined several risk behaviors including anal intercourse, sexual 
experiences abroad, use of drugs or alcohol, and being a current smoker. Among other 
risk behaviors previously discussed (i.e., contraception use, number of partners, etc.) this 
study found that the unvaccinated group was more likely to have experienced anal 
intercourse as their last sexual contact (OR=4.43; 95% CI=1.23-14.29) and to be a 
current smoker.70 Smoking status is an important factor to examine because smoking is 
also a risk factor for cervical cancer, even when controlling for the effects of HPV 
infection and other potential cofactors.78,79 
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2.4.4 Biological Outcomes 
Along with reporting behavioral outcomes, several studies also examined 
biological outcomes (n=9, 45%). For the purposes of this review, they have been divided 
into two general categories: STI testing/diagnosis and pregnancy (including a composite 
measure of STI and pregnancy)/abortions. 
 
2.4.4.1 STI/HIV Testing or Diagnosis 
 All of the studies in this subset had some measure of STI testing or diagnosis. Of 
the studies that examined STI or HIV testing or diagnosis, none of them found HPV 
vaccination to increase STI rates. Of the cross-sectional studies, one (Liddon et al. 2012) 
found no association between HPV vaccination and receiving STI services in the past 
year in both the 15 to 19 and the 20 to 24 year old age groups.64 Two cross-sectional 
studies examining reported STI diagnoses66,69 and one examining HIV serology70 found 
no significant differences between the vaccinated and unvaccinated groups. Additionally, 
one study (Sadler et al. 2015) found that unvaccinated women were more likely to have 
received a positive Chlamydia trachomatis diagnosis (OR=2.3; 95% CI=1.06-5.00).70  
Two longitudinal studies (Cummings et al. 2012 and Jena et al., 2015) examined 
the association between STIs and HPV vaccination.40,73 One cohort study by Jena et al. 
(2015) found that the difference-in-difference odds ratios in the year after vaccination 
was similar between the vaccinated and unvaccinated cohorts.40 This held true for both 
the 12 to 14 and the 15 to 18 year-old groups. Another cohort study found no differences 
in Chlamydia or Trichomoniasis rates between vaccinated and matched unvaccinated 
cohorts.73  
  41  
 
 
2.4.4.2 Abortion/Pregnancy or a Composite Measure of STI and Pregnancy 
 Several studies used composite measures of STI diagnosis and pregnancies. One 
cohort study (Bednarczyk et al. 2012) looked at a composite measure of testing or 
diagnosis of Chlamydia trachomatis infection, pregnancy, or venereal disease not 
otherwise specified (referred to as testing/diagnosis/counseling) found that girls receiving 
HPV vaccine did not have significantly higher rates of testing/diagnosis/counseling for 
these conditions. They found the same results when they examined diagnosis-only rates 
between the vaccinated and unvaccinated groups.41 Another cohort study (Smith et al. 
2015) found no statistically significant differences in a composite measure of STIs and 
pregnancy in relation to HPV vaccination. This result held true when STIs and pregnancy 
were examined separately as well.75  
Studies also examined pregnancy and abortions individually. Sadler et al. (2015) 
found no association between vaccination status and abortion (referred to in the paper as 
“termination,” p=0.85).70 Another (Lutringer-Magnin et al. 2013) assessed abortion rates 
between vaccinated and unvaccinated groups found that 7.1% of their population had had 
an abortion and all of these participants were unvaccinated.42 Additionally, a study with a 
population between 13 and 23 years of age found that unvaccinated women were more 
likely to have been pregnant (20% vs. 8.6%, p=0.016), a result that runs contrary to the 
notion of risk compensation.69  
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2.5 Discussion 
There have been several studies examining the association between HPV 
vaccination using self-report or biological markers of increased risky sexual behaviors. 
Twenty studies were identified for this systematic review. The included studies were all 
published between 2011 and 2015 and varied in study design and sample size. Each of 
the studies had limitations and the results of each individual research effort should be 
interpreted with caution. However, when this body of literature is examined as a whole, 
with similar findings reported across studies, the evidence consistently indicates that 
HPV vaccination does not lead to risk compensation/sexual disinhibition. The finding 
that adolescents do not appear to respond to vaccination with increased risky sexual 
behavior suggests no support for RCT as applied to HPV vaccination. This conclusion is 
supported both by studies that focused on self-reported sexual behavior as well as studies 
that examined biological markers of risk (e.g., STI diagnosis). 
Furthermore, there appeared to be more support for the fact that vaccinated 
women actually showed less involvement in risky behaviors than unvaccinated women, 
which was evidenced by lower numbers of sexual partners and increased use of 
contraception. This finding is not entirely surprising in light of previous research 
reporting that pro-health behaviors tend to cluster together, such that a person who 
engages in one protective health behavior (e.g., getting vaccinated) is more likely to 
engage in another (e.g., using condoms).80 Additionally, an HPV vaccination visit to a 
healthcare provider may present families and providers with opportunities to discuss and 
promote health and disease prevention behaviors. 
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Several studies that examined risk perception merit discussion, even though they 
did not meet the inclusion criteria for the systematic review, and therefore were not 
presented in the Results section. Some of these studies examined the perception of risk in 
a completely vaccinated sample and compared a decreased risk perception post-
vaccination to subsequent sexual behaviors. These studies found that vaccinated 
individuals perceived a need for safer sexual behavior after vaccination.39,81,82 It is 
notable that these studies’ findings were consistent with the results of studies included in 
this review. Furthermore, authors of a recent literature review of HPV vaccine attitudes 
and uptake found that the concern about risk compensation following vaccination was a 
“myth” rather than a valid concern.83 
This systematic review does have limitations so conclusions should be drawn with 
caution. First, the studies included are heterogeneous in both population and outcome 
definitions, which could reduce the specificity and precision of the findings. This issue is 
common in systematic reviews of this nature. For instance, one recent systematic review 
examining HPV vaccination or vaccine intent found varied evidence between HPV 
vaccination or vaccine intent and sexual behavior primarily due to the heterogeneous 
nature of the included studies.84 At the same time, the fact that similar results are reported 
across studies that varied so widely in methodology and population, suggests that the 
findings of no association between vaccination and sexual risk compensation are robust. 
Secondly, the desire to engage in risky sexual behavior might cause a person to seek out 
vaccination which would make it appear that the vaccinated group practices more risky 
sexual behavior. This can be difficult to assess, particularly in cross-sectional studies 
because, as some research has shown, there are times when physicians have vaccinated 
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their patients based on perceived risk status.13,76,77 This should not be confused with an 
implication that the vaccination is the cause of the risky behavior. Finally, this review of 
the literature is reliant on the findings of the studies included in the review. Each of these 
individual studies had limitations of their own including: a lack of a comparison group, 
recall bias, and social desirability of responses, among others. Nevertheless, this study 
thoroughly examined three different databases with relevant search terms in order to 
capture the appropriate studies. To our knowledge, this is the first systematic review 
examining the association (or lack thereof) between HPV vaccination and subsequent 
sexual behaviors and adds credibility to the literature by combining the results and 
showing there is no consistent, replicated evidence of sexual disinhibition after HPV 
vaccination. 
 
2.6 Conclusion 
 The consistent, replicated evidence found across the 20 studies examined in this 
systematic review provides a strong body of evidence refuting an association between 
HPV vaccination and risky sexual behavior. The 20 different studies, utilizing at least 
four distinct study designs and including a total of 521,879 participants, found no 
evidence of increased numbers of sexual partners, younger age of sexual initiation, 
decreased use of contraception (including both condoms and hormonal contraceptives), 
increased STI diagnoses, increased pregnancy rates, or increased history of abortion 
among those vaccinated against HPV. In fact, some studies found vaccinated women 
showed lower risky behaviors than unvaccinated women, indicating a tendency toward 
less risky health behaviors. These findings should alleviate parental and provider 
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concerns that HPV vaccination will lead to risky sexual behaviors. Furthermore, as others 
have noted, even if risk compensation was identified as an issue related to HPV 
vaccination, this would not be justification for withholding vaccination, but would argue 
for effective pre- and post-vaccination counseling.83 
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CHAPTER 3 
HEALTHCARE PROVIDERS’ BELIEFS AND ATTITUDES REGARDING RISK 
COMPENSATION FOLLOWING HPV VACCINATION: A QUALITATIVE 
ANALYSIS 
3.1 Abstract 
Background 
Provider recommendation is one of the strongest predictors of HPV vaccine 
uptake. Research has shown that concerns regarding risk compensation could cause some 
providers to hesitate recommending the HPV vaccine.  
Methods 
During 15 to 30 minute semi-structured interviews in early 2015, 22 U.S. 
pediatric providers were asked about their beliefs regarding sexual disinhibition and 
cervical cancer screening following HPV vaccination. Providers were asked if these 
beliefs result in reservations in their recommending the vaccine. Interviews were audio-
recorded, transcribed, and analyzed using inductive content analysis. 
Results 
None of the providers believed the HPV vaccine would result in risky sexual 
behavior. Half indicated it was better to start vaccination early, before sexual activity was 
a worry. Others noted that patients’ risky behavior decisions happen independently of 
vaccination. When providers were asked if they were concerned about decreased cervical 
cancer screening, half said they did not know and some stated they had never thought 
about it before. The main themes addressed were the significant time lapse between 
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vaccination and screening and that women tend to get over-screened as opposed to under-
screened.  
Conclusion 
Providers were generally in favor of HPV vaccination and did not perceive risk 
compensation as a barrier to HPV recommendation. 
 
Keywords for indexing:  
Behavior, Risk compensation, Sexual disinhibition, HPV vaccination, Cervical cancer 
screening, Healthcare provider 
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3.2 Introduction 
In 2015 the Centers for Disease Control and Prevention (CDC) estimated that 
approximately 79 million Americans were currently infected with human papillomavirus 
(HPV) and 14 million new infections occur every year, making it the most common 
sexually transmitted infection (STI) in the U.S.1 Infection with HPV is a causal factor for 
serious health issues including cervical cancer, anal cancer, penile cancer, oropharyngeal 
cancers, genital warts, and recurrent respiratory papillomatosis.  
Currently there are three different vaccines against HPV licensed by the U.S. 
Food and Drug Administration (FDA). The bivalent vaccine (2vHPV) protects against 
HPV types 16 and 18.45 These two HPV types are responsible for about 70% of cervical 
cancer diagnoses worldwide. The quadrivalent vaccine (4vHPV) protects against HPV-16 
and 18, as well as HPV-6 and 11, which cause about 90% of the cases of genital warts.46 
The FDA licensed a 9-valent HPV vaccine (9vHPV) in December, 2015. This vaccine 
protects against the four types included in 4vHPV as well as five additional oncogenic 
types and has the potential to prevent up to 80% to 90% of cervical cancers.47 The 
2vHPV vaccine is licensed for females ages 9 to 26 and the 4vHPV vaccine is licensed 
for both males and females ages 9 to 26. The Advisory Committee on Immunization 
Practices (ACIP) routinely recommends HPV vaccination for boys and girls age 11 to 12 
and catch up vaccination for women up to age 26, all men up to age 21, and for men who 
have sex with men up to age 26.7 The 9vHPV vaccine was licensed for women ages 9 to 
26 and men ages 9 to 15 in December, 2014.9 In February, 2015, the ACIP issued the 
same age-based recommendations for the 9-valent vaccine as it did for 4vHPV.8  
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HPV vaccination rates in the U.S. remain very low.10 In 2014, only 60.0% of 
adolescent girls and 41.7% of adolescent boys between the ages of 13 and 17 received 
one or more doses in the HPV vaccine series.11 The numbers are even lower for series 
completion (39.7% of girls and 21.6% of boys) Barriers to HPV vaccination include cost 
of the vaccine, lack of knowledge about HPV transmission, and parental concerns about 
vaccinating their children against a sexually transmitted infection (STI).12 Recent 
research has shown that a sizeable portion of physicians (27%) do not strongly endorse 
the HPV vaccine and do not deliver timely recommendations (26% for girls, 39% for 
boys).13 This is of particular concern because one of the strongest predictors of vaccine 
uptake is healthcare provider (HCP) recommendation and a lack of HCP recommendation 
for the HPV vaccination has been listed as a reason for non-vaccination among those who 
are unvaccinated.14-18  
One concern among parents, clinicians, and public health officials that has 
received particular attention in the media is that the introduction of the HPV vaccine may 
lead to risk compensation. These beliefs can be explained by a broader health belief 
theory known as Risk Compoensation Theory. This theory states that each person has an 
innate set point for risk and if some aspect of risk is reduced, he or she will increase risky 
behavior in order to get back up to that set point.23,24 Opponents of the HPV vaccine have 
argued that vaccination could cause adolescents to engage in more risky sexual behavior 
(disinhibition) due to a perceived decreased risk of sexually transmitted infections,21 a 
concern that has no empirical support.85 Furthermore, an additional area that is addressed 
when risk compensation is examined is a possibility that women who have received the 
HPV vaccine may be less likely to adhere to cervical cancer screening recommendations, 
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or may cease cervical cancer screening altogether.19,42,43 It is therefore important to 
understand if HCPs are concerned about risk compensation and if these concerns affect 
their HPV vaccination practices.  
The purpose of this study was to understand healthcare provider beliefs 
surrounding risk compensation with regards to sexual behaviors and cervical cancer 
screening adherence and ascertain how these beliefs affect their HPV vaccination 
recommendation practices. In order to increase HPV vaccination rates, the concerns and 
barriers to vaccination need to be addressed. If the principal concerns can be addressed 
and alleviated, vaccine uptake will likely increase with the potential to save thousands of 
lives and billions of dollars in healthcare costs. 
 
3.3 Methods 
3.3.1 Study Participants 
As part of a larger study examining computerized HCP reminders for HPV 
vaccination, we conducted semi-structured in-person qualitative interviews from January 
to March 2015. The study was approved by the Indiana University Institutional Review 
Board and the relevant portion of the interview guide is attached as Appendix B. 
Participants for this study were pediatrician HCPs working in publicly-funded urban 
health clinics, had patients between the ages of 11-12 who were in need of vaccination, 
and consented to be interviewed. All eligible HCPs were contacted via e-mail. Two 
additional follow-up e-mails were sent to each participant who did not respond to the 
initial e-mail. A total of 39 HCPs were eligible to be interviewed and 22 (56.4%) 
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consented and completed the interview. Participants were recruited until saturation was 
reached, that is, until we were acquiring no new information from the interviews.86 
 
3.3.2 Interviews and Data Analysis 
Qualitative methodology is ideal when exploring an area where little is known 
because it allows the investigators to identify, via in-depth probes, personal and 
contextual factors.87 The interviews lasted 15 to 30 minutes and participants were 
compensated with a $50 gift card. After being provided with brief information regarding 
the study, participants were asked about their general beliefs regarding HPV and HPV 
vaccination. They were also asked additional questions for the larger study pertaining to 
the effectiveness and acceptability of computerized reminders prompting HPV vaccine 
recommendation. Finally, HCPs were asked: 1) if they believe their patients will likely 
practice riskier sexual behaviors (for both male and female patients) after they are 
vaccinated, 2) if they believe vaccination will result in their female patients feeling they 
do not need to get screened for cervical cancer, and 3) if either of these issues affect HCP 
recommendations for the HPV vaccination. Along with these questions, demographic 
characteristics reported during the interview and vaccination practices of the providers, 
accessed from EHRs, were also collected.  
Interviews were audio-recorded, transcribed, and analyzed using inductive content 
analysis.88 Transcripts of the interviews were read to identify meaningful themes; two 
investigators then independently coded each interview according to those themes. The 
codes were reviewed and areas of disagreement were resolved through discussion. 
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3.4 Results 
3.4.1 Sample Description 
A total of 39 HCPs were contacted and the sample who agreed to be interviewed 
consisted of 21 physicians and 1 nurse practitioner (17 females, 5 males), all specializing 
in pediatrics. The participants averaged 14 years in practice. The hospital system, 
Eskenazi Health, is one of the five largest safety-net health systems in the U.S. The health 
system contains a 315-bed hospital and nine community health centers located across the 
metropolitan area of Indianapolis. Each community health center provides adult primary 
care, pediatrics, obstetrics, gynecology, and mental health services. Over 70% of the 
pediatric patient population in this healthcare system receives Medicaid benefits, 3.3% 
receives charity care, and 5.5% is self-pay. 
 
3.4.2 Sexual Disinhibition 
None of the HCPs indicated they believed that getting vaccinated against HPV 
would lead a young adolescent to engage in riskier sexual behavior. Within that question, 
five of the HCPs pointed the interviewer to research supporting their opinion. This 
seemed to be an interesting way for the HCP to avoid giving their own personal opinion 
on the matter and instead of stating their personal beliefs, they would state evidence from 
the literature by saying, for example, “I think that’s been shown in not just one 
publication but multiple publications to not be true.” For a list of themes and exemplar 
quotes, see Table 3.1. 
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Table 3.1 Qualitative Themes and Exemplar Quotes 
Concept Theme Exemplar Quotes 
Sexual Disinhibition   
 
Sexual behaviors are 
independent of vaccination 
"…it's case dependent. So you have those children who are going to be 
more at risk, but you have a majority of the children who are not going 
to deal with those type of issues at this early on age." 
"No.  I’m really not…they’re going to do what they want to do anyway.  
It’s a good time to educate them, of course, but I’d rather just protect 
them.  It doesn’t really give them a license to do anything." 
“[T]he reasons why teenagers engage in sex, risky or not, are really 
multi-factorial and the degree to which vaccination status plays into it is 
probably zero-to-none." 
“This is about the idea that the vast majority of people at some point in 
their life are sexually active.  And so we want this protection before that 
starts.” 
 
Patients are unaware of the 
purpose of vaccination 
"Kids don't have an idea of what shots they really get... [Children] go 
glossy eyed and not even listening…they’re just concerned about how 
many shots they’re getting, but they don’t know what they’re for." 
"My thoughts are that most adolescents don't know which vaccines they 
have or haven't gotten.  And so the idea that they would so aware of it 
that it would influence their behaviors is a little far-fetched and there's 
also data to say that's not true.” 
 
No support for disinhibition in 
the literature 
"I think the literature doesn’t support that. I think there might be parents 
who think that, but I think there’s no evidence of it." 
"I very much go back to the data on we don't decide when to give 
people shots based on behavior, we decide on when they're most 
efficacious.  Like, we know you mount your best immune response 
during this window, so the vaccine is most effective for people if they 
get it at this time.” 
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Table 3.1: Qualitative Themes and Exemplar Quotes (continued) 
 No support for disinhibition in 
the literature 
“I think that’s been shown in not just one publication but multiple 
publications to not be true.” 
Decrease in cervical 
cancer screening 
  
 
Physicians haven’t thought 
about it 
"I don’t know.  I don’t know, actually.  It’s a good question.  I’ve never 
suggested that, or implied that, or even thought about it, so I would 
think that the patients probably haven’t made that connection, would be 
my guess." 
"There are so many reasons why the girls that I vaccinate or the boys 
that I vaccinate are going to fall out of care that the HPV vaccine has 
truthfully not crossed my worry" 
"I don't know the data around this one- I haven't looked for that data 
specifically" 
"That's a really interesting point that you're brining up now" 
 
Women are unaware of the 
purpose of a Pap smear 
"I honestly don’t think most people know why they’re getting pap 
smears, but everybody kind of expects to get one. So I haven’t 
experienced that or heard that at all with people saying, ‘Oh, I don’t 
need to get pap smears now.’” 
"I think they might make the connection with cervical cancer because 
that’s—I talk about that. But I don’t know that they make a connection 
between that and not needing to get a Pap smear.” 
“They’re not thinking about cervical cancer so we’re trying to explain 
what we’re doing it for but I’m not sure they really make the 
connection.” 
 
Time lag between vaccination 
and Pap testing 
"No, because I think by the time our girls are going for Pap screens they 
are going to have forgotten that they got HPV vaccines.  So no, I don't 
think it will.  I don't think it will impact them getting Pap smears. I hope 
it won't...  I don't know that it's that deep.” 
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Table 3.1: Qualitative Themes and Exemplar Quotes (continued) 
 
Time lag between vaccination 
and Pap testing 
“[H]onestly I don’t know if they recollect and maybe we don’t put those 
pieces together, you know, later on." 
“I think a majority of the kids I see that we do start the HPV are usually 
10, 11, 12 so those conversations, ten years from now when you’re 
going for you annual exams, don’t forget to do this, this, and this, it’s 
probably not going to be appropriate.” 
“I don’t think that when they’re 21 years old, that link is -- they’re 
thinking in their head, ‘Oh, well I got the shot 10 years ago, I’m not 
going to get my pap now.’ I just think that link is too long.” 
"I would agree that I think the teenagers aren’t thinking that far ahead. 
They have risky behavior anyway, so I don’t know that this has 
anything to do with it.” 
 
Women tend to get over-
screened 
 "They’re either good about getting their Pap smears and want to get 
them all the time because we actually backed off from yearly Pap 
smears for a lot of people to every three years, but still people want to 
come in every year and get their Pap smear, or people are just not good 
about getting them anyway.  I don’t think the vaccine affects that." 
“[F]olks are typically more resistant to the idea of not having enough 
Pap smears as opposed to feeling overprotected and not needing to go 
get a Pap smear." 
“I actually think that a lot of people will default to getting screened 
more often than they really need to.  There's still a lot of, like, you need 
an annual Pap myth that's out there among the providers and patient.” 
"That's not something I'm particularly worried about and I actually think 
that a lot of people will default to getting screened more often than they 
really need to.” 
  56  
 
3.4.2.1 Belief that sexual behaviors are independent of vaccination 
Half of HCPs specifically mentioned that they feel it is better to start vaccinating 
their patients before sexual activity was a worry. Some felt that this was important in 
order to ensure their patients are protected before they are sexually active and providers 
would communicate this by saying, “This is about the idea that the vast majority of 
people at some point in their life are sexually active.  And so we want this protection 
before that starts.” While other HCPs prefer to vaccinate before sexual activity is a worry, 
so they do not have to talk about sexual activity in the context of vaccination, for 
example, "If somebody asks me—like I usually talk about how [HPV] is the number one 
cause for cervical cancer, and things like that, but I don’t actually talk about sexual 
activity in the context of the vaccine." A participant said they tell their parents, "[Y]ou 
can certainly believe that you can control the behavior of your child, but you certainly 
can't control the behavior of other peoples’ children and that's what immunization is all 
about; herd immunity," indicating that even if a parent states their child does not need it 
because they will abstain from sexual activity until marriage, they cannot predict the 
behavior of their child’s future spouse. One HCP did indicate the opposite belief, stating 
that bringing up sexual activity at a young age would make the parents more averse to 
vaccination. 
Some HCPs believed that in general, people who engage in risky behaviors will 
do so regardless of vaccination status. One said, "[T]he reasons why teenagers engage in 
sex, risky or not, are really multi-factorial and the degree to which vaccination status 
plays into it is probably zero-to-none." This quote echoes the sentiment expressed by 
most of the HCPs which was that vaccinating their patients was a good time to educate 
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them about safe sex but it was better to protect them if at all possible because their 
decision to engage (or not engage) in risky behaviors was independent of vaccination 
status. 
 
3.4.2.2 Patients are unaware of which vaccine they are getting 
One of the crucial components of risk compensation is that the person engaging in 
the risky behavior has to be aware of what the protective behavior is protecting them 
from and they have to understand the connection between the risky behavior and the 
protective behavior. If a patient is not aware that they are getting vaccinated against HPV, 
not aware that HPV is sexually transmitted, or not aware that the vaccine is protecting 
them against a STI, then they will be unlikely to respond to vaccination with riskier 
sexual behavior. Some HCPs indicated that many of their patients do not know or pay 
attention to the vaccines being administered. One participant in the study said, "My 
thoughts are that most adolescents don't know which vaccines they have or haven't 
gotten.  And so the idea that they would [be] so aware of it that it would influence their 
behaviors is a little far-fetched." 
While none of the providers thought sexual disinhibition happened, it should also 
be noted that none of them indicated that it would influence their vaccination practices 
even if they did think it happened. Generally, most of the HCPs seemed almost 
exasperated when they were asked this question with one of them asking, "Is it 
unprofessional for me to say that I think that’s the dumbest thing I’ve ever heard?" 
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3.4.3 Concern about a decrease in cervical cancer screening 
In general, when the HCPs were asked if they thought getting the HPV vaccine 
would result in their patients feeling completely protected from cervical cancer and 
therefore less likely to get screened in the future, half of them (n=11) said they did not 
know and a few (n=3) stated they had not ever thought about it before. If an HCP has not 
even thought about the possibility that their patient might reduce cervical cancer 
screening, the idea that this might be a reason an HCP would be hesitant to recommend 
the vaccine is unfounded. Five of the HCPs said it was an interesting question indicating 
it could be an area for future research in order to educate HCPs on patient behavior post-
vaccination in an attempt to increase vaccine uptake.  
When the HCPs thought about it, all but one of them said they did not think their 
patients would get screened for cervical cancer less often after they were vaccinated. The 
one who did think patients would get screened less stated it more as a fact that she 
thought they did not need to be screened as much and the guidelines would probably 
change soon to allow for decreased screening frequency. She said, “I don’t see why we 
should be doing as frequent cervical or Pap smears if they have an effective vaccine to 
prevent cervical cancer.” 
 
3.4.3.1 Women are unaware of the purpose of a Pap smear 
The HCPs who did not think their patients would get screened less frequently said 
that they believed that most women do not understand the purpose of a Pap smear. 
Therefore, it would be unlikely for the patient to make the connection that the HPV 
vaccine protects against HPV, HPV causes cervical cancer, a Pap smear is a screening 
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test for cervical cancer, and they could therefore reduce their screening. "I think they 
might make the connection with cervical cancer because … I talk about that. But I don’t 
know that they make a connection between that (HPV vaccination) and not needing to get 
a Pap smear.” Or, “They’re not thinking about cervical cancer so we’re trying to explain 
what we’re doing it for but I’m not sure they really make the connection.  With us doing 
Pap smears at later ages anyway, delaying the onset of Pap smears is really not in their 
mind anyway." 
 
3.4.3.2 Time lag between vaccination and Pap testing 
There is also a significant time lapse between the age of vaccination and when a 
woman needs to start cervical cancer screening. Most HCPs indicated they think their 
patients have probably forgotten they were vaccinated and what it was for by the time 
they have to make the decision to get screened. "I think the teenagers aren’t thinking that 
far ahead. They have risky behavior anyway, so I don’t know that this has anything to do 
with it.” 
 
3.4.3.3 Women get over-screened 
Largely, the HCPs indicated the problem they face with their patients is that they 
are screened too often, as opposed to not often enough. They noted that most patients and 
providers are unaware of the current guidelines and tend to think screening should occur 
on a yearly basis. "That's not something I'm particularly worried about and I actually 
think that a lot of people will default to getting screened more often than they really need 
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to.” Some providers have also noted that annual screening is just part of a woman’s 
routine and some of them feel uncomfortable decreasing screening to every three years.  
Even if a reduction in cervical cancer screening was identified, HCPs indicated 
this would not influence their vaccination practices. They said they do not think their 
patients would get screened less but if they did, the HCP would still want to vaccinate as 
many people as possible. They stated preventing cancer is almost always better than 
screening and catching it early. One stated that it is important to emphasize that to the 
patient and said, “Discussing that even though you’ve had the HPV vaccine, this is—this 
(cervical cancer) could still be an issue, so you need to get your regular Pap screens.” 
Furthermore, since there are many other reasons patients fall out of care, the thought that 
they would choose not to continue to be screened for cervical cancer based solely on 
having the HPV vaccination is unlikely. “Like people that don't get Paps, it's not because 
they don’t think they're at risk it's because they're doing resource allocation differently in 
terms of time and money and access to healthcare." 
 
3.5 Discussion 
Our results indicate that none of the HCPs in our sample believed sexual 
disinhibition occurred as a result of HPV vaccination. The HCPs were up-to-date on 
current literature stating that there is no evidence of sexual disinhibition following HPV 
vaccination when examining both biological outcomes and reported sexual 
behaviors.40,41,62,73 Furthermore, HCPs indicated a concern about sexual disinhibition 
would not result in them being hesitant to offer the HPV vaccine to their patients.  
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HCPs also seemed not to be concerned about a decrease in cervical cancer 
screening behavior following HPV vaccination. Most of the providers in this study 
indicated that they did not think patients would decrease cervical cancer screening. They 
indicated several reasons for this belief. The first is that most women do not make a 
connection between HPV, Pap smears, and cervical cancer. The providers in this study 
also stated that frequently women tend to get over screened for cervical cancer and not 
under screened. The providers in this study shared the belief found in similar studies that 
vaccination and screening are both preventive health behaviors and a woman who 
engages in one is more likely to engage in the other due to an emphasis on positive health 
behaviors and access to healthcare. This is consistent with a 2015 study that found that 
unvaccinated women were actually less likely to have had a recent Pap test as compared 
to vaccinated women.89 HCPs in this study indicated that even if they did believe cervical 
cancer screening would decrease, it would not be a reason to withhold vaccination. They 
stated preventing cancer is better than screening so they would prefer to prevent it if at all 
possible.  
This study has some limitations to note. Participants were a convenience sample 
of HCPs in an urban hospital system that generally serves minority and economically 
disadvantaged patients and their responses may not be representative of all HCPs. 
Selection bias might have occurred as the HCPs who agreed to participate might have 
different attitudes to vaccination than the participants who did not wish to participate. 
Furthermore, the face-to-face nature of the study might have contributed to HCPs 
answering questions in a way they deemed socially desirable as opposed to indicating 
their actual personal beliefs. This bias was limited by assuring the participants their 
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individual responses would be kept in strict confidence and all study information would 
be de-identified. 
Opponents of the HPV vaccine have argued that the receipt of the vaccine could 
cause adolescents to engage in more risky sexual behavior due to a perceived decreased 
risk of sexually transmitted infections.21 Some clinicians have expressed concern that 
women who have received the HPV vaccine will be less likely to get screened for 
cervical cancer, or will cease cervical cancer screening altogether.19 Since HCP 
recommendation is one of the strongest predictors of HPV vaccine uptake, it is important 
to understand if HCPs believe risk compensation occurs after HPV vaccination and if this 
belief results in the HCP being hesitant to recommend the vaccine. This is one of the first 
studies to qualitatively analyze HCP beliefs regarding risk compensation in the context of 
both sexual disinhibition and cervical cancer screening.  
 
3.6 Conclusion 
Overall, HCPs in this study indicated they were not concerned about HPV 
vaccination leading to risk compensation. This was true in the context of both sexual 
disinhibition and decreases in cervical cancer screening behaviors. Furthermore, the 
reasons HCPs cited for their lack of concern, including patients not knowing what they 
have been vaccinated against, women not understanding the connection between HPV 
and Pap screening, and women’s preferences for over-screening are also areas that are 
necessary to examine in future research. This study is the first of its kind to examine HCP 
beliefs regarding disinhibition following HPV vaccination and adds to the growing body 
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of literature that disinhibition does not occur post-vaccination and is not a reason for non-
vaccination. 
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CHAPTER 4 
DIFFERENCES IN CERVICAL CANCER SCREENING KNOWLEDGE, 
PRACTICES, AND BELIEFS: AN EXAMINATION OF A LOCAL SURVEY OF 
WOMEN 
4.1 Abstract 
Background 
This study examined the relationship between cervical cancer screening rates and 
human papillomavirus (HPV) vaccination.  
Methods 
We conducted a cross-sectional survey of 21 to 35 year-old women attending a 
local minority health fair in July 2015. The outcomes assessed were: receiving a 
Papanicolaou (Pap) test within the last three years, awareness and comfort with current 
cervical screening recommendations, and knowledge regarding the purpose of a Pap test.  
Results 
A total of 291 survey participant women were included in the analyses. Their 
mean age was 28.5 years and 62% were non-Hispanic black. Most (84%) had received a 
Pap test in the last three years and one-third (33%) had received at least one HPV 
vaccine. Logistic regression results showed that women who had been vaccinated did not 
have lower odds of having a Pap test in the past three years (OR=1.32; 95% CI=0.66-
2.65). In fact, in an adjusted multivariable logistic regression that controlled for age and 
race, vaccinated women were significantly more likely to have had a Pap test 
(AOR=3.06; 95% CI=1.37-6.83). Two-thirds (64%) of respondents thought average-risk 
women should get a Pap test every year. Only 26% of women knew the purpose of a Pap 
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test and the proportion who correctly answered this question varied by race. Participants 
who answered incorrectly were over four times as likely to be non-Hispanic black as 
compared to those who were white (OR=4.20; 95% CI=2.00-8.81; p<0.001). 
Conclusion 
Analysis of this sample of women shows that women who have been vaccinated 
for HPV are more likely to have been screened for cervical cancer. Furthermore, women 
were unaware of the purpose of a Pap test and current screening recommendations.  
Impact 
These results should alleviate concerns among healthcare providers regarding 
whether would decrease cervical cancer screening due to HPV vaccination. A lack of 
knowledge regarding the purpose of a Pap test and current recommendations are areas for 
future interventions. 
 
Keywords for indexing: 
Cancer screening, cervical cancer, HPV vaccination, knowledge, risk compensation 
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4.2 Introduction 
The Centers for Disease Control and Prevention (CDC) estimates 79 million 
Americans are currently infected with human papillomavirus (HPV) and 14 million new 
infections occur every year, making it the most common sexually transmitted infection 
(STI) in the U.S.1 Infection with HPV results serious health issues including cervical 
cancer, anal cancer, penile cancer, oropharyngeal cancers, genital warts, and recurrent 
respiratory papillomatosis.3  
Currently there are three different HPV vaccines licensed by the U.S. Food and 
Drug Administration (FDA): a bivalent (2vHPV), a quadrivalent (4vHPV), and a nine-
valent (9vHPV) vaccine. A series of three doses is required for each vaccine.7 Detailed 
information about all of the vaccines can be found in Petrosky et al. 8.  The Advisory 
Committee on Immunization Practices (ACIP) routinely recommends HPV vaccination 
for boys and girls age 11 or 12 and catch up vaccination for women up to age 26, all men 
up to age 21, and for men who have sex with men up to age 26.7 The 9vHPV vaccine was 
licensed for women ages 9 to 26 and men ages 9-15 in December, 2014.9 In February, 
2015, the ACIP issued the same age-based recommendations for 9vHPV as it did for 
4vHPV.8  
HPV vaccination rates  in the U.S. remain lower than desired to best protect the 
population against HPV infection.10 In 2014, only 60.0% of adolescent girls and 41.7% of 
adolescent boys between the ages of 13 and 17 received one or more doses in the HPV 
vaccine series.11 The percentages are even lower for series completion (39.7% of girls 
and 21.6% of boys). Barriers to HPV vaccination include cost of the vaccine, lack of 
knowledge about HPV transmission, and parental concerns about sexual disinhibition as a 
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result of vaccinating their children against a STI.12 An additional concern is that women 
who have received the HPV vaccine may be less likely to seek screening for cervical 
cancer, or will cease cervical cancer screening altogether due to their perceived lack of 
susceptibility to all cervical cancers.19-22  
Compared to sexual disinhibition, there has been less research conducted on 
cervical cancer screening behavior post-HPV vaccination, particularly regarding 
knowledge and uptake among minority women. Studies have shown that non-Hispanic 
black women have higher incidence of cervical cancer90 and are less likely to get 
screened91 than their white counterparts. One study found cervical cancer screening 
awareness was lower in ethnic minorities. However, this study did not assess knowledge 
and examined minorities in England, which constitute largely different groups than 
minorities in the United States.92 Preliminary studies assessing knowledge about cervical 
cancer screening recommendations have shown that women are generally unaware of 
screening guidelines.43 This is understandable considering cervical cancer screening 
guidelines have changed four times in the last 30 years and the most recent 
recommendations have only been in place since 2012.93 The current CDC 
recommendations for average risk women state that women should be screened with a 
Papanicolaou (Pap) test every three years from age 21 to 29. That screening period can be 
extended to five years from age 30 to 65 if the woman has an HPV DNA test along with 
the Pap test and both are negative. Screening is not recommended after age 65.94 One 
study of 193 college-aged women found that 28% incorrectly thought HPV vaccinated 
and unvaccinated women could get screened at different frequencies. This knowledge did 
not differ based on the participants’ vaccination status.43 Other studies have found similar 
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results in which Pap screening was either positively associated with vaccination or no 
association was found.95-97 Using a national dataset, one of these studies found that a 
lower percentage of women who had not initiated the HPV vaccination series reported 
having a recent Pap test as compared to women who had initiated the series (81.0% vs. 
90.5%).89 The findings of research to date suggest that the impact of having been 
vaccinated against HPV on women’s participation in cervical cancer screening is not yet 
well understood particularly within minority populations.   
The current study examined the relationship between HPV vaccination and Pap 
testing using responses to a survey of mostly minority women. We used both quantitative 
and qualitative methodology in order to: 1) examine if cervical cancer screening rates 
differed between those who had been vaccinated and those who had not; 2) assess if 
women understood the purpose of a Pap test; and 3) assess if women were aware of the 
current recommendations for Pap testing and their comfort level with the current 
recommendation. 
 
4.3 Materials and Methods 
4.3.1 Participants and Procedures 
This survey data collected at a minority health fair was approved by the Indiana 
University Institutional Review Board and conducted in July 2015. The target population 
was women between the ages of 21 to 35 who attended the 46th Annual Indiana Black 
Expo event in Indianapolis. This is one of the nation’s largest cultural events for African-
Americans and draws an estimated 40,000 attendees from across Indiana as well as from 
surrounding states.  The minority health fair is a component offered at the Indiana Black 
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Expo event. Visitors to the health fair were invited to participate in the survey if they met 
the study criteria.  
Exclusion criteria included women with a hysterectomy and women who received 
the vaccine less than three years prior to the survey because there would not be sufficient 
time to assess their post-vaccination screening behaviors. A total of 317 women started 
the survey; 291 of them were included in analysis after excluding those with a history of 
hysterectomy (n=8), those who were vaccinated for HPV less than three years ago 
(n=13), and those who started but did not complete the survey (n=5). It was not possible 
to determine the declination rate due to the nature of the study setting. The oldest age that 
women are recommended to receive the HPV vaccination is 26 years old; therefore, if a 
woman was vaccinated at age 26 when the vaccine became available in 2006, that woman 
would have been 35 years old in 2015. Women between the ages of 21 and 35 are eligible 
for both HPV vaccination and cervical cancer screening.  
 
4.3.2 Measures 
The web-based survey was administered via notebook computers. Questions were 
modeled after relevant items from the National Health Interview Survey (NHIS), a 
population survey administered by the Centers for Disease Control and Prevention. The 
questions assessed if participants received the HPV vaccine, how many shots they 
received, and at what age. We also assessed if participants ever had a Pap test, if they had 
a Pap test in the last 12 months, and when they had their last Pap test. We then expanded 
on the NHIS questions by asking if participants were aware of the new cervical cancer 
screening recommendations and how comfortable they were with the frequency of the 
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screenings in the new recommendations. We also asked open-ended questions to assess if 
participants knew the purpose of a Pap test and the connection between vaccination and a 
Pap test by asking, “What is the purpose of a Pap smear or Pap test?” and “What is the 
connection between HPV vaccination and Pap testing?” The relevant portion of the 
survey is attached as Appendix C. 
 
4.3.3 Analysis 
4.3.3.1 Quantitative Analysis 
The main outcome assessed was whether the women were up-to-date on cervical 
cancer screenings. Women who indicated they had been screened within the last three 
years were considered current; women who indicated their last screening was over three 
years ago or had never been screened were considered not current. We compared the 
demographic characteristics of women who were current with women who were not 
current using bivariate analyses. Demographic variables independently related to Pap 
testing behaviors, derived from the bivariate analyses, were further analyzed using 
multivariable logistic regression to assess the impact of HPV vaccination on cervical 
cancer screening status, controlling for the potential confounding variables. In order to 
explain the interaction between age and vaccination status, stratified logistic regression 
models were conducted separately for each age group in five-year increments. 
Additionally, we assessed women’s knowledge and comfort with cervical cancer 
screening guidelines using frequency tables and regression analyses. All quantitative 
analyses were performed using SPSS v. 22.0 (IBM Corp., Armonk, NY, USA). P-values 
less than 0.05 were considered statistically significant. 
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4.3.3.2 Qualitative Analysis 
The survey included open-ended questions which were analyzed using inductive 
content analysis.88 Responses to questions were assessed to identify meaningful themes. 
Two investigators (MLK & SW) independently coded each response according to those 
themes. The coded responses were reviewed and areas of disagreement were resolved 
through discussion. For one of the questions, “What is the purpose of a Pap smear or Pap 
test,” participants were assessed on whether they correctly answered the question. In 
order to consider the response to the question correct, the participant had to indicate that a 
Pap test checks for cancer or abnormal cells of the cervix. If a participant did not mention 
the cervix, or she indicated the test also checks for STIs, she was marked as answering 
the question partially correct. All other answers were considered incorrect. Answers were 
discussed until a consensus could be reached. With this qualitative coding, we could then 
assess racial differences between those who answered correctly and those who did not. In 
order to assess racial disparities in knowledge regarding cervical cancer screening, we 
examined differences in answers between non-Hispanic blacks and non-Hispanic whites. 
For these questions only, we excluded women who indicated that their race was 
“Hispanic,” “other” and “multiracial” because the number of respondents were relatively 
small and heterogeneous. Therefore, all analyses commenting on differences in 
knowledge between non-Hispanic blacks and non-Hispanic whites were conducted as 
bivariate analyses with participants in the “Hispanic,” “other” and “multiracial” category 
coded as missing. 
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4.4 Results 
4.4.1 Sample Description 
A full description of the respondents, including differences by screening status, is 
shown in Table 4.1.  The respondents’ ages ranged from 21 to 35 with a mean of 28.5 
(standard deviation=4.7). Race was assessed by self-report and nearly two-thirds of the 
respondents (62.5%, n=182) were non-Hispanic black; the rest self-identified as non-
Hispanic white (22.7%, n=66) or Hispanic, other, or multiracial (14.8%, n=43). A 
majority of the women in the study received a Pap test in the last three years (84.2%, 
n=245), and one-third (n=97) had received at least one HPV vaccination. There were also 
demographic differences in the bivariate comparisons between the participants who were 
current on their Pap testing as compared to those who were not. As compared to those 
who were current on their cervical cancer screening, those who were not current were 
more likely to be younger (p<0.001) and Hispanic, other, or multiracial (p=0.004).  
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Table 4.1 Sample Description by Cervical Cancer Screening Status (Current vs. Not 
Current) 
 Total Sample  
(n=291) 
Current 
(n=245) 
Not Current 
(n=46) 
Bivariate 
analysis 
p-value 
Mean Age 28.5 29.1 25.3 <0.001* 
Race    0.004* 
Non-Hispanic White 22.7% 22.9% 21.7%  
Non-Hispanic Black 62.5% 65.3% 47.8%  
†Other 14.8% 11.8% 30.4%  
Education    0.112 
Some high school/high 
school graduate/GED 
12.0% 11.0% 17.4%  
Some college/trade 
school/4-year degree 
52.9% 55.5% 39.1%  
Some post-grad/ 
graduate degree 
35.1% 33.5% 43.5%  
HPV Vaccine Status    0.497 
Received >=1 dose 33.3% 34.3% 28.3%  
Never received HPV 
vaccine or unsure 
66.7% 65.7% 71.7%  
Purpose of a Pap Test    0.317 
Incorrect 35.7% 34.3% 43.5%  
Partially Correct 37.8% 39.6% 28.3%  
Correct 26.5% 26.1% 28.3%  
Pap Recommendation 
Awareness 
   <0.001* 
Aware  45.4% 50.0% 21.7%  
Unaware 54.3% 50.0% 78.3%  
Guideline Comfort    0.005* 
Very uncomfortable 21.6% 24.2% 8.9%  
Somewhat 
uncomfortable 
21.0% 21.3% 20.0%  
Neither comfortable nor 
uncomfortable 
17.5% 16.0% 26.7%  
Somewhat comfortable 13.4% 11.1% 26.7%  
Very comfortable 25.8% 27.5% 17.8%  
*The difference between those who were current and those who were not current for a 
Pap test was significantly different between groups at p<0.05. 
†“Other” category includes people who indicated “other” for their race, people who 
indicated multiple races, and Hispanics. 
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4.4.2 Quantitative Results 
4.4.2.1 Association between HPV Vaccination and Cervical Cancer Screening 
In bivariate logistic regression, women who indicated receiving at least one HPV 
vaccine were not less likely to have received a Pap test when compared to unvaccinated 
women (OR=1.32; 95% CI=0.66-2.65; p=0.427). In contradistinction to the prediction of 
risk-compensation theory, multivariable logistic regression, which controlled for the 
independently significant demographic variables age and race, showed that vaccinated 
women were actually more likely to obtain the cervical cancer screening than their non-
vaccinated counterparts (AOR=3.06; 95% CI=1.37-6.83; p=0.006). For all regression 
analyses, see Table 4.2.  
An interaction analysis was then performed to assess if age was the driver in the 
relationship between vaccination status and Pap testing. The interaction between age and 
vaccination status was then entered into the model and was statistically significant 
(OR=1.62; 95% CI=1.05-2.50; p=0.003). In order to explain this relationship between 
age and vaccination status, stratified logistic regression models were conducted 
separately for three age groups, defined in five-year increments. We found that the 
relationship between vaccination status and cervical cancer screening frequency was not 
significant for 21 to 25 year olds while controlling for race (OR=2.0; 95% CI=0.8-5.0). 
For the 26 to 30 and 31 to 35 age groups, of the women who were overdue for Pap testing 
(n=9 and 7 respectively), none had been vaccinated for HPV. We then performed a 
Fisher’s exact test and found that the relationship between vaccination status and Pap 
testing was significant for the middle age group (p=0.03) but was not significant for the 
youngest or oldest age groups (p=0.13 and 0.59, respectively).   
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Table 4.2 Regression Analyses Assessing the Receipt of a Pap Test in the Last Three 
Years Controlling for Demographic Variables 
 Bivariate  
Odds Ratio (95% CI) 
Multivariable 
Odds Ratio (95% CI) 
Ever received HPV vaccine   
No Ref Ref 
Yes 1.32(0.66-2.65) 3.06 (1.37-6.83)* 
Race   
Non-Hispanic White  Ref Ref 
Non-Hispanic Black 1.30(0.58-2.91) 0.94 (0.39-2.27) 
Other 0.37(0.15-0.94)* 0.30 (0.11-0.82)* 
Age (continuous) 1.21(1.12-1.31)* 1.26 (1.15-1.38)* 
†Education   
Some high school/high 
school graduate/GED (ref) 
Ref  
Some college/trade 
school/4-year degree 
2.24(0.88-5.67)  
Some post-grad/ graduate 
degree 
1.22(0.48-3.07)  
*Significant at p<0.05 
†These variables were not significant in the bivariate analysis and were 
subsequently excluded from multivariable regression model. 
 
 
4.4.2.2 Beliefs about Post-Vaccination Screening Frequency 
When asked if vaccinated women should get screened less frequently than 
unvaccinated women, 17% (n=50) incorrectly said “yes,” 68% (n=198) said “no,” and 
15% (n=43) said they did not know. Women who answered the question correctly were 
no more likely to have had a Pap test in the last three years than women who answered 
the question incorrectly (OR=1.18; 95% CI=0.48-2.92; p=0.72). However, response 
patterns varied by HPV vaccination status, in that women who answered the question 
correctly were more likely to be vaccinated than women who answered it incorrectly 
(OR=2.77; 95% CI=1.31-5.85; p=0.008). The accuracy of the responses to the question 
about whether HPV vaccinated women should be screened for cervical cancer at a 
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different frequency than non-vaccinated women also varied by race; participants who 
answered incorrectly were more likely to be non-Hispanic black than participants who 
answered correctly (OR=3.19; 95% CI=1.27-7.97; p=0.013).  
When asked how often a woman should get a Pap test if she has never had 
cervical cancer or an abnormal Pap test, 64% (n=187) incorrectly responded they thought 
she should get screened every year. There were variations by race; those who answered 
incorrectly had double the odds of being be non-Hispanic black (OR=2.0; 95% CI=1.11-
3.58). Women were then told the current recommendation for average risk women is 
every three years and were asked if they were aware of this recommendation. Almost half 
(45.3%, n=132) indicated they were aware of the recommendation. Of the women who 
were aware of the current recommendation, 53% (n=70) indicated that they knew the 
recommendation was every three years, but still stated the women should get screened 
every year. When asked on a five-point scale how comfortable they were with the new 
screening recommendations (from very uncomfortable to very comfortable), 43% 
(n=124) indicated they were either very or somewhat uncomfortable, 40% (n=114) 
reported they were either very or somewhat comfortable, and 18% (n=51) indicated they 
were neither comfortable nor uncomfortable.  
 
4.4.3 Qualitative Results 
4.4.3.1 Understanding of the Purpose of a Pap Test 
At the beginning of the survey, prior to defining the term “Pap smear.” 
respondents were asked “What is the purpose of a Pap smear or Pap test?” in order to 
measure awareness. Almost half (49%, n=143) stated that a Pap smear checks for cancer, 
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although not all participants knew it tested specifically for cervical cancer. Additionally, 
20% (n=57) stated it checked for abnormal or precancerous cells and 41% (n=119) knew 
that a Pap smear checks the cervix. Some were vague in their answers suggesting they did 
not fully understand the purpose of a Pap test for example, 9% (n=25) indicated that a 
Pap smear checked for STIs in general and 4% (n=11) indicated the Pap smear was a test 
for the presence of HPV. An additional 25 women (9%) stated the Pap smear checked for 
“disease” but did not specifically say what disease. Some participants thought a Pap 
smear tested other body parts including the ovaries, uterus, breasts, and generic terms 
such as “organs” and “down there.” Almost one-third (29%, n=85) gave generic answers 
such as “to make sure everything is okay” and “to check for abnormalities.” These 
categories are not mutually exclusive and most of the women answered in a way that they 
were counted in more than one category.  
 We also examined whether participants answered the question about the purpose 
of a Pap test correctly or incorrectly. We examined the total sample using the previously 
described system for measuring correctness, 77 women (26%) answered correctly, 110 
women (38%) were partially correct, and 104 women (36%) answered incorrectly. We 
then excluded the “other” race category and compared non-Hispanic blacks and non-
Hispanic whites on whether they answered this question correctly. Correct answers varied 
by race and participants who answered incorrectly had more than four times the odds of 
being non-Hispanic black as compared to those who answered correctly (OR=4.20; 95% 
CI=2.00-8.81; p<0.001). A breakdown of percentages who answered correctly in the 
sample of just the non-Hispanic black and white groups as well as differences between 
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races and exemplar quotes of what was qualitatively coded as correct, partially correct, 
and incorrect, are all included in Table 4.3. 
   
 
7
9
 
Table 4.3 Comparison between Non-Hispanic Blacks and Non-Hispanic Whites and their answers to “What is the purpose of a Pap 
smear or Pap test?” 
Purpose of a 
Pap 
Overall 
n (%) 
Non-Hispanic 
White 
n (%) 
Non-Hispanic 
Black 
n (%) 
Example Quotes 
Correct 64 (25.8) 29 (43.9) 35 (19.2) “For early detection of cancerous cells in the 
cervix.” 
“Screening test which detects pre-cancerous 
or cancerous cervical cells.” 
“Screening for cervical cancer.” 
Partially 
Correct 
93 (37.5) 22 (33.3) 71 (39.0) “The check for any abnormalities and to 
screen for cervical cancer as well as STDs.” 
“Check for healthy/non-healthy cells.” 
“To check up on feminine health. It is a 
preventative screening.” 
“To ensure there are no abnormalities that 
may lead to ovarian or cervical cancer.” 
Incorrect 91 (36.7) 15 (22.7) 76 (41.8) “To determine if you possibly have breast 
cancer.” 
“Check for irregular uterine cells.” 
“…to collect cervical cells for testing of 
STDs, viruses, etc.” 
“To check for STDs and make sure 
everything is good with female organs.” 
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4.5 Discussion 
4.5.1 Behaviors and Beliefs around Vaccination and Cervical Cancer Screening 
We examined a convenience sample of mostly non-Hispanic black women 
surveyed to obtain data needed to compare cervical cancer screening practices between 
HPV vaccinated and unvaccinated women. We also examined their knowledge regarding 
the purpose of a Pap test, current screening recommendations, and their level of comfort 
with the current screening recommendations. In contrast to the prediction of risk-
compensation theory, the results suggest no relationship between vaccination status and 
subsequent cervical cancer screening behaviors. Moreover, when the relationship is 
examined controlling for age and race of the respondent, we found that women who had 
been vaccinated had a three times greater odds of having been screened for cervical 
cancer within the last three years. This is consistent with our multivariable regression 
analysis findings in that vaccinated women generally were more likely to obtain the 
cervical cancer screening than unvaccinated women. It is also consistent with recent 
research that used a national sample and found uptake of Pap testing was lower among 
those who had not initiated the HPV vaccination series.89  
Most women knew that HPV vaccinated women are recommended to obtain 
cervical cancer screening at the same frequency as unvaccinated women. Results varied 
by vaccination status but did not vary by whether the women were current on their 
cervical cancer screenings. The majority of women thought an average-risk woman 
should get screened every year, even though 45% of women claimed to know that the 
recommendation changed to every three years. This might be because the participants did 
not like admitting they were unaware of current screening recommendations or it may be 
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indicative of how uncomfortable women may be with the new screening 
recommendations. More women were uncomfortable than comfortable with the new 
screening recommendations and almost one-fifth were neither comfortable nor 
uncomfortable, which might suggest that the problem is not that women are unaware of 
the current screening recommendations but rather that they are uncomfortable with them. 
This could be an area for a future intervention targeted at reminding physicians to educate 
their patients on the purpose of Pap tests and the current cervical cancer screening 
recommendations as well as for a broader public health campaign aimed at increasing 
knowledge around current cervical cancer screening guidelines.  
 
4.5.2 Cervical Cancer Screening Beliefs and Understanding 
Most women knew that Pap testing checked for cancer or abnormal cells but less 
than half knew it was checking the cervix. Some women thought a Pap test checked for 
the presence of HPV. While abnormal cervical cells might indicate the presence of HPV, 
a negative Pap test does not indicate the absence of HPV. This could be a point of 
confusion for some women. Additionally, women believed they were being checked for 
additional STIs during the course of a Pap test and some thought they were also being 
checked for uterine or ovarian cancer. Only one-fourth of the sample correctly answered 
the question stating a Pap test checked for cervical cancer only.  
We wanted to explore if risk compensation in the form of decreased cervical 
cancer screening could happen after HPV vaccination. In order for risk compensation to 
happen, women would have to understand three different concepts: 1) That the HPV 
vaccine protects against HPV, 2) that HPV causes cervical cancer, and 3) that a Pap 
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smear checks for cervical cancer. This question would have been more effective if asked 
in an in-person interview in which the interviewer could ask probing questions since 
some of the incorrect responses could have been due to an unclear question, as opposed 
to a lack of understanding of the concept. However, as it was asked, it seemed that 
women did not seem to understand that the HPV vaccine is a primary prevention measure 
for cervical cancer and Pap screening is secondary prevention for cervical cancer. 
Because women do not understand that Pap screening checks for something that HPV 
vaccination prevents, it is not reasonable that risk compensation in the form of decreased 
cervical cancer screening would occur among HPV-vaccinated women.  
 
4.5.3 Racial Disparities in Cervical Cancer Knowledge 
There were racial disparities seen in questions concerning knowledge of cervical 
cancer screening. Non-Hispanic black participants were less likely than their white 
counter-parts to be aware that vaccinated women should be screened at the same 
frequency as unvaccinated women and fewer of them were aware of current screening 
recommendations. They were also less likely to correctly identify the purpose of a Pap 
smear which means that not only are non-Hispanic black women substantially less aware 
of screening recommendations, but they also lack a fundamental knowledge regarding the 
purpose of a Pap test. This could be due to differences in education between the two 
groups but also indicates there is significant room for improvement in educating 
particularly minority women regarding the purpose of and guidelines for cervical cancer 
screening. It is important for healthcare providers to know about these differences in 
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order to target minority women for educational opportunities and tailor their education 
and screening messages that would be sensitive to the needs of different populations. 
 
4.5.4 Limitations 
This study gathered survey data from a convenience sample, thus the women in 
the sample may not be representative of the general population. However, our survey 
results were consistent with those from previous studies.89 The measures for receipt of 
HPV vaccination and Pap screening were both self-reported and are subject to recall bias 
and reporting errors. However, since we were examining a behavioral outcome, it should 
be noted that for this study it was more important to know if the woman believed she was 
vaccinated as opposed to knowing if she was actually vaccinated.  
 
4.6 Conclusion 
The current study extends previous work in a national sample and was replicated 
more recently in a sample with a different sociodemographic make-up and sampling 
methodology. This kind of replication helps to support the generalizability of the 
findings. If risk compensation in the form of decreased cervical cancer screening were to 
occur, we’d expect to see an inverse relationship between vaccination and screening 
practices. However, we found that screening practices between the vaccinated and 
unvaccinated participants were not significantly different. In the multivariable analysis 
we found that there was a positive relationship between vaccination and cervical cancer 
screening when adjusted for age and race. Therefore, there is no evidence that risk 
compensation due to HPV vaccination is occurring and in fact, it appears as if the 
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opposite is occurring. This finding adds credibility to the hypothesis that the reason for 
higher screening rates among vaccinated women may have more to do with access to 
healthcare and pro-health attitudes rather than a false sense of security leading to 
decreased screening. A strength of this study is that it included a large number of 
minority participants. Findings from this study may assist healthcare providers in 
tailoring messages to their patients based on their specific needs. 
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CHAPTER 5 
CONCLUSIONS 
 
Findings from the three studies provide important insights about risk 
compensation after HPV vaccination. Taken together, the results of these three studies do 
not support the Risk Compensation Theory in the context of HPV vaccination. The 
findings holds true in the context of sexual behaviors as well as cervical cancer screening 
and could have implications for clinical practice or future interventions aimed at 
increasing vaccination uptake.  
In regards to sexual disinhibition, the research findings presented in this 
dissertation found that there was no evidence of increased risky sexual behaviors after 
HPV vaccination. This was evidenced by the systematic review across 20 including a 
total of 521,879 participants that found no evidence of increased numbers of sexual 
partners, younger age of sexual initiation, decreased use of contraception (including both 
condoms and hormonal contraceptives), increased STI diagnoses, increased pregnancy 
rates, or increased history of abortion among those vaccinated against HPV. In fact, some 
studies found vaccinated women showed lower risky behaviors than unvaccinated 
women, indicating a tendency toward less risky health behaviors.  
The Risk Compensation Theory was not supported when examining HPV 
vaccination and subsequent adherence to cervical cancer screening guidelines. If risk 
compensation in the form of decreased cervical cancer screening were to occur, we would 
expect to see an inverse relationship between prevalence of HPV vaccination and 
screening practices. However, what we found in the bivariate analysis was that screening 
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practices between the vaccinated and unvaccinated participants were not statistically 
different. The multivariable analysis found there was actually a positive relationship 
between vaccination and cervical cancer screening when adjusted for age and race. 
Therefore, there’s contrary evidence that risk compensation is occurring. The finding 
adds credibility to the hypothesis that the reason for higher screening rates among 
vaccinated women may have more to do with access to healthcare and pro-health 
attitudes rather than a false sense of security leading to decreased screening. Furthermore, 
there were significant racial disparities in terms of knowledge regarding cervical cancer 
screening. Since knowledge is positively associated with vaccine uptake, 98,99 it is 
important to be aware of disparity when creating interventions for vaccine uptake and 
targeting programs for specific populations. 
One of the strongest predictors of vaccine uptake is recommendations by HCPs. It 
is important to know if there is concern about risk compensation from the HCPs and if 
this could be a reason HCPs are hesitant to strongly recommend the vaccine.98,100  This 
research found that overall, HCPs indicated they were not concerned about HPV 
vaccination leading to risk compensation. This was true in the context of both sexual 
disinhibition and decreases in cervical cancer screening behaviors. Furthermore, the 
reasons HCPs cited for their lack of concern, included patients not knowing what they 
have been vaccinated against, women not understanding the connection between HPV 
and Pap screening, and women’s preferences for over-screenings. These are also 
important areas to examine in future research.  
In conclusion, Risk Compensation Theory was not supported in the context of 
HPV vaccination. The findings from this dissertation research should alleviate concerns 
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that physicians and parents may have about HPV vaccination for youth. There are several 
areas for future research including how to better tailor interventions at the community 
level to increase knowledge and awareness among the minority populations. There is also 
a need for broader public health campaigns aimed at dispelling the myths associated with 
HPV vaccination and advocating for vaccine uptake.  
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APPENDIX A: Observational Study Data Extraction Sheet for Behavioral Outcomes  
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APPENDIX B: Qualitative Interview Guide 
 
[Interviewer]: It has been suggested that getting vaccinated against HPV could lead a 
young adolescent to engage in riskier sexual behavior because they might believe they 
are protected from the negative consequences of those actions. 
 
1. What are your thoughts about this issue? 
 
2. As a provider, do you believe HPV vaccine could lead your patients to practice riskier 
sexual behaviors in the future?  If yes, why?  If no, why not? 
2.A. If yes, does this concern have any influence on your HPV vaccination 
practices? [who/when you vaccinate?] 
 
Some people wonder if a young woman who is vaccinated against HPV might be less 
inclined to get screened for cervical cancer as an adult. 
 
3. What are your thoughts about this issue? 
 
4. Do you believe the HPV vaccine could result in your patients feeling protected  from 
cervical cancer and they are therefore less likely to get screened for cervical cancer in the 
future?   
4.A. If yes, why?  If no, why not? 
4.B. If yes, does this concern have any influence on your HPV vaccination 
practices? [who/when you vaccinate?] 
 
5. Do you discuss the importance of cervical cancer screening in the future regardless of 
HPV vaccination status? 
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APPENDIX C: INShape Indiana Black and Minority Health Expo Questionnaire 
1. How old are you? 
Under 21 
21-35 
36-50 
Over 50 
2. Please type in your exact age ___________________ 
3. What is your sex?  (circle one )      
Female Male  Other  
4. Have you had a hysterectomy?  
 Yes No I don’t know  
5. What is your race? (mark all that apply )  
White/European  
Black/African American Asian   
Native Hawaiian/Pacific Islander  
Native American/Alaskan Native  
Other   
6. Are you Latina/Hispanic? 
 Yes  No 
7. What is the highest grade you completed in school? 
Some high school  
High school graduate or GED  
Trade school or some college   
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4-year college degree  
Some post-college education  
Graduate degree  
8. What is the purpose of a Pap smear or Pap test? (Open-ended response) 
 
9. How often should you get a Pap test? (Open-ended response) 
 
10. What is the connection between HPV vaccine and Pap testing? (HPV stands for 
human papillomavirus (pap-uh-LOW-muh-vi-rus), the vaccines are sometimes called 
CERVARIX or GARDASIL). (Open-ended response) 
 
11. Should women who have been vaccinated for HPV get a Pap test less frequently than 
women who haven’t received the vaccine?  
 Yes No I don’t know 
 
12. Have you ever received an HPV shot or vaccine? Yes No I don’t know 
 
13. How many HPV shots did you receive? ________________________ (Skip if answer 
to 13 was “no” or “I don’t know”) 
 
14. How old were you when you received your first HPV shot? ______________ (Skip if 
answer to 13 was “no” or “I don’t know”) 
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15. Have you ever had a pap test? (A Pap smear or Pap test is a routine test for women in 
which the doctor examines the cervix, takes a cell sample from the cervix with a small 
stick or brush, and sends it to the lab.) 
 Yes no  I don’t know 
 
16. Have any of your pap tests been abnormal? 
 Yes No I don’t know Prefer not to answer 
 
17. Have you had a Pap smear or Pap test during the past 12 months? (A Pap smear or 
Pap test is a routine test for women in which the doctor examines the cervix, takes a cell 
sample from the cervix with a small stick or brush, and sends it to the lab.) (Skip if the 
answer to 16 was “no” or “I don’t know”) 
 Yes no I don’t know 
 
18. When did you have your most recent Pap smear or Pap test? (Skip if the answer to 16 
was “no” or “I don’t know”) 
 A year ago or less 
More than 1 year but not more than 2 years 
More than 2 years but not more than 3 years 
More than 3 years but not more than 5 years 
Over 5 years ago 
Don't know  
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19. Was your most recent pap test abnormal? 
 Yes No I don’t know Prefer not to answer 
 
20. When do you expect to have your next Pap smear or Pap test? 
A year or less from now  
More than 1 year to 3 years from now  
More than 3 years to 5 years from now  
More than 5 years from now  
When doctor recommends it  
Never, had HPV DNA test  
Never, had HPV vaccine  
Never, other reason  
Don't know  
 
21. If a woman has never had cervical cancer or an abnormal Pap test, how often should 
she get a Pap test? 
Every year 
Every 1-2 years 
Every 3-5 years 
Every 5-10 years 
I don't know  
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22. In 2012 the recommendation for Pap testing for most women went from every year to 
every three years. Did you know this? 
Yes No 
 
23. How comfortable are you with this new screening recommendation? 
Very uncomfortable 
Somewhat uncomfortable 
Neither comfortable nor uncomfortable 
Somewhat comfortable 
Very comfortable  
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